Skip to Main Content
Book cover for Oxford Handbook of General Practice (4 edn) Oxford Handbook of General Practice (4 edn)
Chantal Simon et al.

A newer edition of this book is available.

Close

Contents

Book cover for Oxford Handbook of General Practice (4 edn) Oxford Handbook of General Practice (4 edn)
Chantal Simon et al.
Disclaimer
Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always … More Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

Automatic responses. The reflex arc goes from the stimulus via a sensory nerve to the spinal cord and then back along a motor nerve to cause muscle contraction, without brain involvement.

See Table 16.2. Record whether absent, present with reinforcement, normal, or brisk ± clonus.

Table 16.2
Key reflexes and nerve roots involved
Reflex Test Expected result Nerve roots

Jaw

Ask the patient to let his mouth open slightly. Place a finger on the chin and tap the finger with a tendon hammer

Contraction of masseters and closure of mouth

Vth cranial nerve

Gag

Touch the back of the patient’s pharynx on each side with a spatula, If absent, ask the patient whether he can feel the spatula—if he can, then Xth nerve palsy

Contraction of the soft palate

IXth/Xth cranial nerve

Biceps

Tap a finger placed on the biceps tendon by letting the tendon hammer fall on it

Contraction of the biceps + elbow flexion

C5, C6

Supinator

Tap the lower end of the radius just above the wrist with the tendon hammer

Contraction of brachioradialis + elbow flexion

C5, C6

Triceps

Support elbow in flexion with one hand. Tap the triceps tendon with a tendon hammer held in the other hand

Contraction of triceps + elbow extension

C7, C8

Knee

Support the knees so that relaxed and slightly bent. Let the tendon hammer fall onto the infrapatellar tendon

Contraction of quadriceps + extension of knee

L3, L4

Ankle

Externally rotate the thigh and flex the knee. Let the tendon hammer fall onto the Achilles tendon

Contraction of gastrocnemius + plantar flexion of the ankle

S1

Abdominal

Lightly stroke the abdominal wall diagonally towards the umbilicus in each of the four abdominal quadrants

Abdominal wall contractions. When absent can be normal or indicate UMN or LMN lesion

T7–T12

Cremaster

♂ patients only. Pre-warn the patient. Stroke the superior and medial aspect of the thigh in a downwards direction

Contraction of cremasteric muscle → raising of scrotum and testis on the side stroked. Absent in UMN and LMN lesions

L1

Anal

Scratch the perianal skin

Reflex contraction of the external sphincter. Absent in UMN and LMN lesions

S4, S5

Plantar

Pre-warn the patient. Run a blunt object up the lateral side of the sole of the foot, curving medially before the MTP joints

Flexion of big toe (if >1y old). Extension implies UMN lesion

S1

Reflex Test Expected result Nerve roots

Jaw

Ask the patient to let his mouth open slightly. Place a finger on the chin and tap the finger with a tendon hammer

Contraction of masseters and closure of mouth

Vth cranial nerve

Gag

Touch the back of the patient’s pharynx on each side with a spatula, If absent, ask the patient whether he can feel the spatula—if he can, then Xth nerve palsy

Contraction of the soft palate

IXth/Xth cranial nerve

Biceps

Tap a finger placed on the biceps tendon by letting the tendon hammer fall on it

Contraction of the biceps + elbow flexion

C5, C6

Supinator

Tap the lower end of the radius just above the wrist with the tendon hammer

Contraction of brachioradialis + elbow flexion

C5, C6

Triceps

Support elbow in flexion with one hand. Tap the triceps tendon with a tendon hammer held in the other hand

Contraction of triceps + elbow extension

C7, C8

Knee

Support the knees so that relaxed and slightly bent. Let the tendon hammer fall onto the infrapatellar tendon

Contraction of quadriceps + extension of knee

L3, L4

Ankle

Externally rotate the thigh and flex the knee. Let the tendon hammer fall onto the Achilles tendon

Contraction of gastrocnemius + plantar flexion of the ankle

S1

Abdominal

Lightly stroke the abdominal wall diagonally towards the umbilicus in each of the four abdominal quadrants

Abdominal wall contractions. When absent can be normal or indicate UMN or LMN lesion

T7–T12

Cremaster

♂ patients only. Pre-warn the patient. Stroke the superior and medial aspect of the thigh in a downwards direction

Contraction of cremasteric muscle → raising of scrotum and testis on the side stroked. Absent in UMN and LMN lesions

L1

Anal

Scratch the perianal skin

Reflex contraction of the external sphincter. Absent in UMN and LMN lesions

S4, S5

Plantar

Pre-warn the patient. Run a blunt object up the lateral side of the sole of the foot, curving medially before the MTP joints

Flexion of big toe (if >1y old). Extension implies UMN lesion

S1

Implies a breach in the reflex arc at:

Sensory nerve or root, e.g. neuropathy, spondylosis

Anterior horn cell, e.g. MND, polio

Motor nerve or root, e.g. neuropathy, spondylosis

Nerve endings, e.g myasthenia gravis, or

Muscle, e.g. myopathy

Implies lack of higher control—an upper motor neurone lesion, e.g. post-stroke.

Rhythmic involuntary muscle contraction due to abrupt tendon stretching, e.g. by dorsiflexing the ankle—associated with an UMN lesion.

Method of accentuating reflexes. Use if a reflex seems absent. Ask patients to clench their teeth (to reinforce upper limb reflexes) or clench their hands and pull in opposite directions (to accentuate lower limb reflexes). This effect only lasts ~1s, so ask patients to perform the manoeuvre simultaneously with the tap from the tendon hammer.

See Table 16.1

Table 16.1
Quick screening test for muscle power
Joint Movement Nerve roots Joint Movement Nerve roots

Shoulder

Abduction

C5,6

Hip

Flexion

L1–3

Adduction

C6–8

Extension

L4,5 & S1

Elbow

Flexion

C5,6

Knee

Flexion

L5 & S1

Extension

C7,8

Extension

L3,4

Wrist

Flexion

C7,8

Ankle

Dorsiflexion

L4,5

Extension

C6,7

Plantarflexion

S1,2

Fingers

Flexion

C8

Toes

Extensors

L5,S1

Extension

C7

Flexors

S2

Abduction

T1

Joint Movement Nerve roots Joint Movement Nerve roots

Shoulder

Abduction

C5,6

Hip

Flexion

L1–3

Adduction

C6–8

Extension

L4,5 & S1

Elbow

Flexion

C5,6

Knee

Flexion

L5 & S1

Extension

C7,8

Extension

L3,4

Wrist

Flexion

C7,8

Ankle

Dorsiflexion

L4,5

Extension

C6,7

Plantarflexion

S1,2

Fingers

Flexion

C8

Toes

Extensors

L5,S1

Extension

C7

Flexors

S2

Abduction

T1

graphic Test proximal muscle power by asking the patient to sit from lying, pull you towards him/herself, or rise from squatting.

Table 16.3 summarizes cranial nerve lesions and their causes. Figure 16.1 shows the cutaneous innervation of the head and neck. Cranial nerves may be affected at any point from the nerve nucleus within the brainstem to the point of innervation. Think systematically about the level of the lesion. Potential sites:

Muscle

Neuromuscular junction

Along the course of the nerve outside the brainstem

Within the brainstem

Table 16.3
Cranial nerve lesions and their causes
Nerve Clinical test Causes

I Olfactory

Smell—test each nostril for the ability to differentiate different smells

Trauma, frontal lobe tumour, meningitis

II Optic

Acuity—Snellen chart

Visual fields—compare with your own visual fields by standing directly in front of the patient with your head at the same level as theirs

Pupils—size, shape, reaction to light, and accommodation

Ophthalmoscopy—darken room, dilate pupil with 1 drop tropicamide 0.5% if needed, view optic disc (? pale, swollen), follow each vessel outwards to view each quadrant, track outwards to check lens and cornea

Monocular blindness—lesion in one eye or optic nerve (e.g. MS, giant cell arteritis)

Bitemporal hemianopia—optic chiasm compression, e.g. pituitary adenoma, craniopharyngioma, internal carotid artery aneurysm

Homonymous hemianopia—affects half the visual field on the side opposite the lesion. Caused by lesion beyond the optic chiasm, e.g. stroke, abscess, tumour

III

Ptosis, large pupil, eye looks down- and outwards

graphic Diplopia from a 3rd nerve lesion may cause nystagmus

DM, giant cell arteritis, syphilis, posterior communicating artery aneurysm, idiopathic

If pupil normal size, results fom DM or other vascular cause

IV

Diplopia on looking down and in; may compensate by tilting head

Rare in isolation. May occur as a result of trauma to the orbit

V Trigeminal

Motor—open mouth. Jaw deviates to the side of the lesion

Sensory—corneal reflex lost first. Check all three divisions

Motor—bulbar palsy (graphic p. 549), acoustic neuroma

Sensory—trigeminal neuralgia (graphic p. 549); herpes zoster; nasopharyngeal carcinoma

VI

Horizontal diplopia on looking outwards

MS, pontine CVA, ↑ ICP

VII Facial

Causes facial weakness and droop

Ask to raise eyebrows, show teeth, puff out cheeks.

LMN lesion: all one side of face affected

UMN lesion: lower two-thirds of the face affected only

LMN—Bell’s palsy, polio, otitis media, skull fracture, cerebello pontine angle tumour, parotid tumour, herpes zoster (Ramsay Hunt syndrome graphic p. 538)

UMN—stroke, tumour

VIII Vestibulo- auditory

Auditory—ask to repeat a number whispered in 1 ear whilst you block the other

Vestibular—ask about balance, check for nystagmus (graphic p. 950)—ask patient to fix on finger ¾ m away—check gaze upwards, downwards, lateral (both directions), keeping finger <30° from midline

Noise, Paget’s disease, Ménière’s disease (graphic p. 951), herpes zoster, acoustic neuroma, brainstem CVA, drugs (e.g. furosemide)

IX, X

Gag reflex, palate moves → normal side on saying ‘Aah’

Trauma, brainstem lesions, neck tumours

XI

Trapezii—shrug shoulders against resistance

Sternomastoid—turn head to right/left against resistance

Rare. Polio, syringomyelia, tumours near jugular foramen, stroke, bulbar palsy (graphic p. 549), polio, trauma, TB

XII

Tongue deviates to the side of the lesion

Trauma, brainstem lesions, neck tumours

Nerve Clinical test Causes

I Olfactory

Smell—test each nostril for the ability to differentiate different smells

Trauma, frontal lobe tumour, meningitis

II Optic

Acuity—Snellen chart

Visual fields—compare with your own visual fields by standing directly in front of the patient with your head at the same level as theirs

Pupils—size, shape, reaction to light, and accommodation

Ophthalmoscopy—darken room, dilate pupil with 1 drop tropicamide 0.5% if needed, view optic disc (? pale, swollen), follow each vessel outwards to view each quadrant, track outwards to check lens and cornea

Monocular blindness—lesion in one eye or optic nerve (e.g. MS, giant cell arteritis)

Bitemporal hemianopia—optic chiasm compression, e.g. pituitary adenoma, craniopharyngioma, internal carotid artery aneurysm

Homonymous hemianopia—affects half the visual field on the side opposite the lesion. Caused by lesion beyond the optic chiasm, e.g. stroke, abscess, tumour

III

Ptosis, large pupil, eye looks down- and outwards

graphic Diplopia from a 3rd nerve lesion may cause nystagmus

DM, giant cell arteritis, syphilis, posterior communicating artery aneurysm, idiopathic

If pupil normal size, results fom DM or other vascular cause

IV

Diplopia on looking down and in; may compensate by tilting head

Rare in isolation. May occur as a result of trauma to the orbit

V Trigeminal

Motor—open mouth. Jaw deviates to the side of the lesion

Sensory—corneal reflex lost first. Check all three divisions

Motor—bulbar palsy (graphic p. 549), acoustic neuroma

Sensory—trigeminal neuralgia (graphic p. 549); herpes zoster; nasopharyngeal carcinoma

VI

Horizontal diplopia on looking outwards

MS, pontine CVA, ↑ ICP

VII Facial

Causes facial weakness and droop

Ask to raise eyebrows, show teeth, puff out cheeks.

LMN lesion: all one side of face affected

UMN lesion: lower two-thirds of the face affected only

LMN—Bell’s palsy, polio, otitis media, skull fracture, cerebello pontine angle tumour, parotid tumour, herpes zoster (Ramsay Hunt syndrome graphic p. 538)

UMN—stroke, tumour

VIII Vestibulo- auditory

Auditory—ask to repeat a number whispered in 1 ear whilst you block the other

Vestibular—ask about balance, check for nystagmus (graphic p. 950)—ask patient to fix on finger ¾ m away—check gaze upwards, downwards, lateral (both directions), keeping finger <30° from midline

Noise, Paget’s disease, Ménière’s disease (graphic p. 951), herpes zoster, acoustic neuroma, brainstem CVA, drugs (e.g. furosemide)

IX, X

Gag reflex, palate moves → normal side on saying ‘Aah’

Trauma, brainstem lesions, neck tumours

XI

Trapezii—shrug shoulders against resistance

Sternomastoid—turn head to right/left against resistance

Rare. Polio, syringomyelia, tumours near jugular foramen, stroke, bulbar palsy (graphic p. 549), polio, trauma, TB

XII

Tongue deviates to the side of the lesion

Trauma, brainstem lesions, neck tumours

 Cutaneous innervation of the head and neck
Figure 16.1

Cutaneous innervation of the head and neck

Reproduced from
Simon C (2006) Neurology, with permission from Oxford University Pressreference
.

graphic Any cranial nerve may be affected by DM, MS, tumours, sarcoid, vasculitis or syphilis and >1 nerve may be affected by a lesion. Refer according to cause to ENT, ophthalmology, or neurology.

See Figure 16.2 (graphic p. 540) and Figure 16.3 (graphic p. 541).

 Dermatomes and peripheral nerve distribution
Figure 16.2

Dermatomes and peripheral nerve distribution

 Dermatomes and peripheral nerve distribution
Figure 16.3

Dermatomes and peripheral nerve distribution

Lesions of individual peripheral (including cranial) nerves. Causes: trauma, compression, DM, leprosy. If >1 peripheral nerve is involved, the term mononeuritis multiplex is used. Causes: DM, sarcoid, cancer, PAN, amyloid, leprosy.

See Table 16.4.

Table 16.4
Common mononeuropathies
Nerve involved Nerve roots Presentation Common causes

Median

C5–T1

Loss of sensation over lateral 3½ fingers and palm.

Wasting of the thenar eminence

Inability to flex the terminal phalanx of the thumb implies involvement of the anterior interosseous branch

Trauma (especially wrist lacerations), carpal tunnel syndrome (graphic p. 486)

Ulnar

C7–T1

Weakness and wasting of interossei muscles (weakness of abduction of fingers) and claw hand deformity.

Wasting of hypothenar eminence, sensory loss over medial 1½ fingers and ulnar side of the hand.

Flexion of 4th and 5th fingers is weak if proximal lesion

Trauma or compression at the elbow (graphic p. 482), trauma at the wrist

Radial

C5–T1

Sensory loss is variable but always includes the dorsal aspect of the root of the thumb.

Wrist drop and weak extension of thumb and fingers

Compression against the humerus, trauma

Sciatic

L4–S2

Weakness of hamstrings and all muscles below the knee (foot drop).

Loss of sensation below the knee laterally

Back injury, pelvic tumour

Common peroneal

L4–S2

Inability to dorsiflex the foot (foot drop), evert the foot, or extend the toes.

Sensory loss over dorsum of the foot

Trauma

Tibial

S1–S3

Inability to stand on tiptoe, invert the foot or flex toes

Sensory loss over sole

Trauma or entrapment

Nerve involved Nerve roots Presentation Common causes

Median

C5–T1

Loss of sensation over lateral 3½ fingers and palm.

Wasting of the thenar eminence

Inability to flex the terminal phalanx of the thumb implies involvement of the anterior interosseous branch

Trauma (especially wrist lacerations), carpal tunnel syndrome (graphic p. 486)

Ulnar

C7–T1

Weakness and wasting of interossei muscles (weakness of abduction of fingers) and claw hand deformity.

Wasting of hypothenar eminence, sensory loss over medial 1½ fingers and ulnar side of the hand.

Flexion of 4th and 5th fingers is weak if proximal lesion

Trauma or compression at the elbow (graphic p. 482), trauma at the wrist

Radial

C5–T1

Sensory loss is variable but always includes the dorsal aspect of the root of the thumb.

Wrist drop and weak extension of thumb and fingers

Compression against the humerus, trauma

Sciatic

L4–S2

Weakness of hamstrings and all muscles below the knee (foot drop).

Loss of sensation below the knee laterally

Back injury, pelvic tumour

Common peroneal

L4–S2

Inability to dorsiflex the foot (foot drop), evert the foot, or extend the toes.

Sensory loss over dorsum of the foot

Trauma

Tibial

S1–S3

Inability to stand on tiptoe, invert the foot or flex toes

Sensory loss over sole

Trauma or entrapment

Facial palsy without other signs. Unknown cause—possibly viral. Peak age: 10–40y. ♂ = ♀. Lifetime incidence: ~1:65. Affects left and right side of the face equally often. Usually sudden onset—may be preceded by pain around the ear. Other possible symptoms: facial numbness; ↓ noise tolerance; disturbed taste on the anterior part of the tongue.

~70% recover completely; 13% have insignificant sequelae; the remainder have permanent deficit. 85% improve in <3wk—reassure. Give prednisolone (25mg bd for 10d) if <72h after onset of symptomsR. Protect eye—tape lid shut and pad at night; glasses in the day ± artificial tears if drying. Refer:

If recovery is not starting after 3wk

For tarsorraphy if complete or long-standing palsy

If unacceptable cosmetic result—may benefit from plastic surgery

C. Bell (1774–1842)—Scottish anatomist and surgeon

Severe pain in the ear precedes facial nerve palsy. Zoster vesicles appear around the ear, in the external ear canal, on the soft palate, and in the tonsillar fossa. Often accompanied by deafness ± vertigo which are slow to resolve and may result in permanent deficit. Pain usually abates after 48h but post-herpetic neuralgia can be a problem. If detected <24h after the rash appears, treatment with antivirals (e.g. aciclovir 800mg 5x/d for 1 wk) may be effective.

J. Ramsay Hunt (1872–1937)—US neurologist.

graphic p. 498

Postural hypotension (dizziness or syncope on standing, after exercise or a large meal), impotence, inability to sweat, vomiting and dysphagia, diarrhoea or constipation, urinary retention or incontinence, Horner’s syndrome (graphic p. 300). Check BP lying and standing—a postural drop of ≥30/15mmHg is abnormal. Causes:

Primary autonomic failure No known cause. Occurs alone or as part of multisystem atrophy. Typically middle-aged/elderly men. Onset is insidious. Survival—rarely >10y after diagnosis

Ageing 25% >74y have postural hypotension. Review medication, discourage prolonged bed rest. Often associated with disordered thermoregulation, making elderly people prone to hypothermia. Exclude other disorders (e.g. DM, multisystem atrophy, drugs) before putting down to ageing alone

Drugs Common culprits—antihypertensives (e.g. thiazides), diuretics (over-diuresis), L-dopa, TCAs, phenothiazines, benzodiazepines

Polyneuropathies May be part of more general polyneuropathy, e.g. DM, Guillain–Barré syndrome, or alcoholic/nutritional neuropathy

Other causes Craniopharyngioma, vascular lesions, spinal cord lesions, tabes dorsalis, Chagas’ disease, HIV, familial dysautonomia

Treat any underlying cause. Advise patients to stand slowly, raise the head of the bed at night, eat little and often, and ↓ carbohydrate and alcohol intake. Fludrocortisone (0.1mg/d, increasing prn–unlicensed) may help those most severely affected. An alternative (also unlicensed) is midodrine. Refer if diagnosis is unclear or simple measures are ineffective.

graphic p. 542

Generalized disorder of peripheral nerves, including cranial and autonomic nerves. Distribution is bilateral, symmetrical, and widespread.

Presents as numbness, tingling, or burning sensation often affecting the extremities first (glove and stocking distribution) or causing clumsiness handling fine objects (e.g. needle).

Presents as progressive weakness or clumsiness of hands, stumbling/falls on walking, respiratory difficulty (can progress rapidly). Examination: wasting and weakness most marked distally; reflexes are ↓ or absent.

See Table 16.5.

Table 16.5
Causes of polyneuropathy

Inflammatory

Guillain–Barré syndrome (mostly motor)

Chronic inflammatory demyelinating polyneuropathy (CDP)

Sarcoidosis

Metabolic

DM (mainly sensory)

Renal failure (mainly sensory)

Hypothyroidism

Hypoglycaemia

Mitochondrial disorders

Vasculitis

Polyarteritis nodosa

Rheumatoid arthritis

Wegener’s granulomatosis

Malignancy

Paraneoplastic syndromes (especially small cell lung cancer)

Polycythaemia rubra vera

Infection

HIV

Syphilis

Lyme disease

Leprosy (mainly sensory)

Vitamin deficiency

Lack of B1, B6, B12 (e.g. alcoholic)

Inherited

Refsum’s syndrome

Charcot–Marie–Tooth syndrome (mostly motor)

Porphyria

Toxins

Lead (mostly motor)

Arsenic

Drugs

Alcohol

Cisplatin

Isoniazid

Vincristine

Nitrofurantoin

Less frequently: metronidazole, phenytoin

Others

Paraproteinaemias, e.g. multiple myeloma, amyloidosis

Inflammatory

Guillain–Barré syndrome (mostly motor)

Chronic inflammatory demyelinating polyneuropathy (CDP)

Sarcoidosis

Metabolic

DM (mainly sensory)

Renal failure (mainly sensory)

Hypothyroidism

Hypoglycaemia

Mitochondrial disorders

Vasculitis

Polyarteritis nodosa

Rheumatoid arthritis

Wegener’s granulomatosis

Malignancy

Paraneoplastic syndromes (especially small cell lung cancer)

Polycythaemia rubra vera

Infection

HIV

Syphilis

Lyme disease

Leprosy (mainly sensory)

Vitamin deficiency

Lack of B1, B6, B12 (e.g. alcoholic)

Inherited

Refsum’s syndrome

Charcot–Marie–Tooth syndrome (mostly motor)

Porphyria

Toxins

Lead (mostly motor)

Arsenic

Drugs

Alcohol

Cisplatin

Isoniazid

Vincristine

Nitrofurantoin

Less frequently: metronidazole, phenytoin

Others

Paraproteinaemias, e.g. multiple myeloma, amyloidosis

Exclude common causes—check blood glucose, FBC, ESR, U&E, Cr and eGFR, LFTs, TFTs, plasma B12, autoimmune profile, syphilis serology.

Treat cause if possible. Involve physiotherapists and OT. If sensory neuropathy care of the feet is important to minimize trauma and consequent disability. Refer if a cause is not found.

graphic If rapid deterioration admit as acute medical emergency as ventilation may be needed.

Presents at puberty or in early adult life and begins with foot drop and weak legs. The peroneal muscles are the first to atrophy. The disease spreads to the hands then arms. Sensation and reflexes are also ↓. Unknown cause. Once diagnosis is confirmed treatment is supportive.

J.M. Charcot (1825–93) and P. Marie (1853–1940)—French neurologists; H.H. Tooth (1856–1925)—English neurologist.

Develops within a few weeks of surgery, flu vaccination or infection (URTI, flu, VZ, HSV, CMV, EBV, Campylobacter, Mycoplasma). In 40% no precipitating event is found.

Presents with ascending motor neuropathy which may advance fast. Proximal muscles are more affected than distal muscles. Trunk, respiratory muscles, and cranial nerves are commonly affected.

If suspected admit immediately to hospital as an emergency. Ventilation on ITU is frequently required; 85% make a complete or near-complete recovery; 10% are unable to walk alone at 1y; mortality is 10%.

C. Guillain (1876–1961) and J.A. Barré (1880–1967)—French neurologists.

graphic p. 579

Rare autosomal recessive disorder which presents in the second decade or later with sensorimotor polyneuropathy, ataxia, visual, and/or hearing problems. Treatment involves dietary restriction (avoidance of chlorophyll-containing foods) and plasmapheresis.

S. Refsum (1907–1991)—Norwegian physician.

graphicWalking difficulty (‘off legs’)

Common symptom in the elderly. Causes:

Musculoskeletal Osteoarthritis or RA, osteoporotic fractures, fractured neck of femur, osteomalacia, Paget’s disease, polymyalgia rheumatica

Psychological Depression, bereavement, fear of falling

Neurological Stroke, Parkinson’s disease, peripheral neuropathy

Spinal cord compression

Systemic Pneumonia, UTI, anaemia, hypothyroidism, renal failure, infection, hypothermia

Management

Treat according to cause. Refer (e.g. to rapid response team, social services, or elderly care) if inadequate support at home, cause warrants referral, or no cause is found.

Gait means manner of walking. Abnormal gait can give clues to the underlying problem.

Normal gait is interrupted by abnormal movements, e.g. choreiform movements, athetoid movements or hemiballismus. May indicate underlying neurological problem, e.g. cerebral palsy, Huntington’s chorea.

Gait adjusts to try to minimize pain in a joint—usually OA hip. The patient leans towards the affected side and takes a rapid step on that side followed by a slower step on the contralateral side—check Trendelenburg’s sign (graphic p. 488).

Apart from alcohol, the other major cause of drunken gait is a cerebellar lesion. Features:

Wide-based gait or reeling gait on a narrow base

Feet are often raised too high and placed over carefully, with the patient looking ahead

If a cerebellar lesion, the patient falls to the side of the lesion

Patients trip frequently or walk with a high stepping gait. On examination, patients are unable to walk on their heels and cannot dorsiflex their foot. Check ankle jerk. Causes:

Common peroneal palsy, e.g. due to trauma—normal ankle jerk

Sciatica—ankle jerk absent

L4, L5 root lesion—ankle jerk may be absent

Peripheral motor neuropathy, e.g. alcoholic—ankle jerk weak or absent

Distal myopathy—ankle jerk weak or absent

Motor neurone disease—↑ ankle jerk

Style of walking seen in patients with UMN lesions. Features:

Arm adducted and internally rotated, elbow flexed and pronated ± finger flexion

Foot is plantar flexed and the leg swings in a lateral arc

Marked unsteadiness—the feet appear stuck to the floor causing a wide-based, shuffling gait.

Seen in patients with Parkinson’s disease and other causes of parkinsonism. Features:

Shuffling gait Short steps, with the feet barely leaving the ground, producing an audible shuffling noise. May trip over small obstacles

Turning ‘en bloc’ Keeping the neck and trunk rigid, and requiring multiple small steps to accomplish a turn

Gait freezing Inability to move feet. May worsen in tight, cluttered spaces or when attempting to initiate gait

Festinant gait Flexed posture as if hurrying to keep up with feet

Lack of normal arm swing

As the name implies, the patient walks as if his/her legs were like a pair of scissors. Associated with spastic paraplegia

Both legs are held rigid with plantar flexion of the ankle, extension of the knee, and adduction/internal rotation of the hips

The patient walks on tiptoe and the knees rub together/cross during the walking cycle

Often accompanied by complex movements of the upper limbs to assist the walking movements

Loss of proprioception due to peripheral neuropathy or spinal cord disease (e.g. cervical spondylosis, MS, syphilis, combined degeneration of the cord) results in an ataxic gait similar to that seen with cerebellar disease. Check Romberg’s test. Features:

Broad-based gait with a tendency to stamp feet down clumsily

Patient tends to look at feet throughout the walking cycle

Romberg’s sign +ve

Typically seen in patients with proximal myopathy, e.g. due to muscular dystrophy. Other causes: pregnancy, congenital dislocation of the hip. Features:

Broad-based gait. The pelvis drops to the side of the leg being raised

The patient moves his/her body and hips to accommodate this, resulting in a duck-like waddle in the swing phase

Commonly accompanied by ↑ forward curvature of the lower spine

Examining gait

Note abnormalities and any aids/assistance required.

Make sure that you can see the legs well

Ask the patient to stand up from a chair without support. If able to do that, repeat with feet together and/or with eyes closed

Ask the patient to stand still with feet together. If able to do that ask the patient to close his eyes and see what happens (Romberg’s sign)

Ask the patient to walk normally for ~5m, turn round, and walk back

Ask the patient to walk heel-to-toe (testing for cerebellar disease)

Ask the patient to stand with the feet together

With eyes open—testing cerebellar and posterior column function

With eyes closed—testing posterior column function

On toes alone—impossible with S1 lesions

On heels alone—impossible if L4/L5 lesion

graphic p. 544

Painful muscle spasm. Common—especially at night and after exercise. Rarely associated with disease—salt depletion, muscle ischaemia, myopathy. Forearm cramps suggest motor neurone disease. Night cramps in the elderly may respond to quinine bisulphate 300mg nocte twice weekly.

Prolonged muscle contraction producing abnormal postures or repetitive movements.

Spasmodic torticollis Head is pulled to one side and held there by a contracting sternomastoid muscle. Treat with physiotherapy

Blepharospasm Involuntary contraction of the orbicularis oculi. If troublesome, consider treatment with diazepam (but be careful to avoid dependence) or refer for treatment with botulinum toxin

Writer’s cramp Spasm of the hand and forearm muscles on writing

Generalized dystonia Primary generalized dystonia is usually genetic. Specialist treatment from a neurologist is essential. First-line drug treatment is with levodopa. If that is ineffective, an anticholinergic drug (e.g. trihexyphenidyl) can be helpful in controlling muscle spasms and tremor. Second-line treatments may include clonazepam, tetrabenazine, baclofen, botulinum toxin injections. Deep brain stimulation may also be helpful

Secondary dystonia Symptoms of dystonia that result from drugs or other medical conditions. Includes: drug-induced dystonia (acute dystonia or tardive dyskinesia); dystonia associated with cerebral palsy; dystonia assosicated with Parkinson’s disease; dystonia associated with other brain injury or disease; and dystonia associated with metabolic conditions (e.g. Wilson’s disease)

Involuntary chewing and grimacing movements, resulting from long-term neuroleptic treatment (metoclopramide and prochlorperazine are also possible causes). Withdraw neuroleptic—if no improvement after 3–6mo consider tetrabenazine 25–50mg tds po.

The Dystonia Society  graphic 020 7793 3650 graphic  www.dystonia.org.uk

Sudden, involuntary focal or general jerks. May be normal, especially if occurs when falling asleep. Other causes:

Neurodegenerative disease (e.g. CJD)

Myoclonic epilepsy

Benign essential myoclonus (generalized myoclonus beginning in childhood as muscle twitches, may be inherited as autosomal dominant)

Asterixis (metabolic flap—e.g liver failure, uraemia)

If needed treat with sodium valproate or clonazepam.

Impairment of performance of complex movements despite preservation of ability to perform their individual components. Test by asking the patient to perform everyday tasks (e.g. ask to dress/undress), copy complex hand movements and do familiar sequences of movements (e.g. ‘head, shoulders, knees, and toes’).

graphic p. 916

Most common causes are stroke or space-occupying lesion. Involve rehabilitation services and OT.

Dressing dyspraxia Patient is unsure of the orientation of clothes on his/her body.

Constructional dyspraxia Difficulty in assembling objects or drawing (ask to draw 5-pointed star)

Gait dyspraxia Gait disorder although the lower limbs function normally—more common amongst the elderly

Resting tremor Present at rest but abolished on voluntary movement. Most common cause—PD when tremor is rhythmic

Intention tremor Irregular large amplitude tremor worse on movement, e.g. reaching for something. Typical of cerebellar disease

Tremors on movement Thyrotoxicosis, anxiety, benign essential tremor (inherited), and drugs (e.g. β-agonists) cause a fine tremor abolished at rest. Alcohol and β-blockers may help

Intermittent lapses of an assumed posture. May involve arms, neck, tongue, jaw, and eyelids. Usually bilateral, absent at rest, and asynchronous on each side. Causes: liver failure (flapping tremor), heart failure, respiratory failure, renal failure, hypoglycaemia, barbiturate intoxication.

Slow, confluent, often rhythmic, purposeless movements of hands, tongue, fingers, or face. Causes: cerebral palsy, kernicterus.

Non-rhythmic, jerky, purposeless movements (especially hands), with voluntary movements possible in between. Most common causes: cerebral palsy, Huntington’s chorea, Sydenham’s chorea.

Large-amplitude, involuntary flinging movements of limbs. May occur after stroke, in Huntington’s disease or with high doses of levodopa for PD.

Brief, repeated, and stereotyped movements which are able to be suppressed voluntarily for a while. Common in children and usually resolve spontaneously. Consider clonazepam or clonidine if tics are severe.

graphic p. 911

graphic p. 936

Disorder of rhythm and fluency of speech in which syllables, words, or phrases are repeated. ♂: ♀ ≈4:1. Cause: unknown. Can result in stress and embarrassment.

Younger children Often short-lived; usually resolves spontaneously

Older children/adults Refer to speech therapy

Difficulty with articulation due to incoordination or weakness of the musculature of speech. Language is normal. Ask to repeat ‘baby hippopotamus’ or ‘British constitution’. Treat the cause if possible otherwise support with speech therapy and aids to communication. Causes: see Table 16.6.

Table 16.6
Causes of dysarthria
Cause Characteristics

Cerebellar disease

Slurring of speech as if drunk

Speech is irregular in volume and scanning in quality

Extrapyramidal disease,

e.g. Parkinson’s disease

Soft, indistinct, and monotonous speech

Pseudo-bulbar palsy,

e.g. stroke (bilateral), MS, MND

Alteration of speech—typically nasal speech sounding like Donald Duck

Difficulty swallowing or chewing

Tongue is spastic and jaw jerk ↑

Bulbar palsy,

e.g. MND, Guillain–Barré, alcoholic brainstem myelinolysis, 1° or 2° brainstem tumours, syringobulbia, polio, hyponatraemia

Speech—quiet, hoarse or nasal

Loss of function of the tongue, muscles of chewing/swallowing ± facial muscles

Flaccid, fasciculating tongue

Jaw jerk normal or absent

Palate paralysis

Nasal speech

Asymmetric or absent gag reflex

Myasthenia gravis

Slurring of speech when fatigued

Cause Characteristics

Cerebellar disease

Slurring of speech as if drunk

Speech is irregular in volume and scanning in quality

Extrapyramidal disease,

e.g. Parkinson’s disease

Soft, indistinct, and monotonous speech

Pseudo-bulbar palsy,

e.g. stroke (bilateral), MS, MND

Alteration of speech—typically nasal speech sounding like Donald Duck

Difficulty swallowing or chewing

Tongue is spastic and jaw jerk ↑

Bulbar palsy,

e.g. MND, Guillain–Barré, alcoholic brainstem myelinolysis, 1° or 2° brainstem tumours, syringobulbia, polio, hyponatraemia

Speech—quiet, hoarse or nasal

Loss of function of the tongue, muscles of chewing/swallowing ± facial muscles

Flaccid, fasciculating tongue

Jaw jerk normal or absent

Palate paralysis

Nasal speech

Asymmetric or absent gag reflex

Myasthenia gravis

Slurring of speech when fatigued

Impairment of language due to brain damage to the dominant hemisphere. The left hemisphere is dominant for 99% of right-handed people and 60% of left-handers. In most cases, due to stroke or brain tumour. Rarely due to head injury or dementia. Assessment and classification: see Table 16.7. Mixed pictures are common. Treatment:

Speech therapy may, or may not, be helpful

Support, e.g. dysphasia groups

Aids to communication, e.g. computers, picture boards

Table 16.7
Assessment and classification of dysphasia

Assessment:

 

Is speech fluent, grammatical, meaningful, and apt? If yes, dysphasia is unlikely.

Comprehension: can the patient follow one, two, or multiple step commands?

Repetition: can the patient repeat a phrase after you?

Naming: can the patient name common and uncommon items?

Reading and writing? Usually affected too. If not, question the diagnosis of dysphasia.

Assessment:

 

Is speech fluent, grammatical, meaningful, and apt? If yes, dysphasia is unlikely.

Comprehension: can the patient follow one, two, or multiple step commands?

Repetition: can the patient repeat a phrase after you?

Naming: can the patient name common and uncommon items?

Reading and writing? Usually affected too. If not, question the diagnosis of dysphasia.

Characteristics of dysphasia Broca’s (expressive) Wernicke’s (receptive) Conduction Transcortical

Fluent?

✓ or ✗

Repetition normal?

Understanding impaired?

✓ or ✗

Characteristics of dysphasia Broca’s (expressive) Wernicke’s (receptive) Conduction Transcortical

Fluent?

✓ or ✗

Repetition normal?

Understanding impaired?

✓ or ✗

Autoimmune disease. Antibodies to the acetylcholine receptor cause a deficit of receptors at the neuromuscular junction → muscle weakness. Antibodies are detectable in 90%. ♀:♂ ≈2:1. Associated with thymic tumours and other autoimmune disease, e.g. RA, SLE, hyperthyroidism. Generally follows a relapsing or slowly progressive course. If thymoma present, 5y survival ≈ 30%.

Young adults with easy fatigability of muscles. Commonly affected muscles are the:

Orbital muscles causing ptosis and diplopia, and

Bulbar muscles causing slurring of speech—ask to count to 50

Weakness is exacerbated by pregnancy, infection, drugs (e.g. β-blockers, opiates, tetracycline, quinine), climate change, emotion, and exercise.

If suspected refer for confirmation by a neurologist and specialist treatment. Treated with:

Anticholinesterase, e.g. pyridostigmine

Immunosuppression with prednisolone, methotrexate, or azathioprine

Thymectomy → remission in 30% and benefit in another 40%

Plasmapheresis

Occurs in association with small cell carcinoma of the lung or rarely autoimmune disease. Differs from myasthenia gravis by the tendency to hyporeflexia. Autonomic involvement is common. Proximal limb muscles/trunk are most commonly involved. Specialist treatment is essential.

Myaesthenia Gravis Association UK graphic  www.mgauk.org

Blackouts, faints, and funny turns are all common presentations to general practice. The major questions which should be asked seeing an individual who has had a funny turn are:

Is it epilepsy?

If it is epilepsy, then what kind?

If it is not epilepsy, then is there another serious underlying cause, e.g. heart disease?

A good history from the patient and ideally from a witness is essential in the correct diagnosis. Ask:

What happened?

When and where? Particularly, did it start during sleep?

Were there any precipitating events?

Were there any warning signs (e.g. aura, feeling going to faint, etc.)?

Does the patient remember the whole episode? If not, which bits are missing and how long are the gaps?

Did the patient lose consciousness? Quite frequently, patients describe episodes of dizziness or unsteadiness/falling as ‘funny turns’

Did the patient jerk his/her limbs? If so, was the jerking generalized or restricted to one area of the body?

What did the patient look like during the attack? An eye witness account is helpful

Did anything else happen during the attack (e.g. tongue biting, incontinence)?

What happened after the attack? Was the patient conscious straight away? Was there disorientation, drowsiness, or headache?

General medical history, including cardiac history and history of other neurological symptoms

Psychiatric history—anxiety, depression, panic attacks?

Past medical history—birth trauma, febrile convulsions in childhood, significant head injury, and/or meningitis/encephalitis

Family history—epilepsy

Substance abuse? Drugs or alcohol?

Complete general and neurological examination. Particularly check for:

Skin changes Café-au-lait spots (neurofibromatosis); adenoma sebaceum (tuberous sclerosis); trigeminal capillary haemangioma (Sturge–Weber syndrome)

Cardiovascular abnormalities Heart rate and rhythm, murmurs, carotid bruits, BP

Focal neurological deficits Suggest presence of a structural neurological lesion

graphic p. 896

graphic p. 574

Abrupt and transient loss of consciousness due to a sudden ↓ in cerebral perfusion. Common—prevalence ~6% adults. It has many causes, ranging from benign (vasovagal syncope) to fatal (sustained ventricular tachycardia); the prognosis depends on the cause.

A typical attack takes the following pattern:

Prodromal symptoms Nausea, clammy sweating, blurring, greying and possible loss of vision, light-headedness, dizziness and tinnitus, yawning. The collection is characteristic

Anoxic phase Loss of consciousness, pallor, sweating, pupil dilatation, tachypnoea, bradycardia. Muscle tone is ↓, causing eyes to roll up and the patient to fall. May be accompanied by a few myoclonic jerks as the patient falls

Recovery In the horizontal position, skin colour, pulse, and consciousness usually return within seconds. graphic If the patient is unable to fall and is kept upright a 2° anoxic seizure may occur

After-effects Confusion, amnesia, and drowsiness are not prolonged. Injury and incontinence are rare but may occur. Tongue biting is very rare

Is the term applied to a less severe attack with partial loss of consciousness and a near fall.

Common. Peripheral vasodilatation, bradycardia, and venous pooling → postural hypotension. Often cause is unclear, though ♀ > ♂. Known precipitants: fright (e.g. during venesection) or emotion. Exclude other reasons for loss of consciousness. No treatment needed—reassure.

Distinguish between true vertigo (the illusion of rotatory movement—the room spinning) and a feeling of unsteadiness or light-headedness:

Vertigo  graphic p. 950

Imbalance Implies difficulty in walking straight, e.g. from disease of peripheral nerves, posterior columns, or cerebellum

Faintness The feeling of being about to pass out. Associated with some seizure disorders and a variety of non-neurological conditions (e.g. postural hypotension, vasovagal fainting; hyperventilation; hypoglycaemia; arrhythmias; cough syncope). Sometimes >1 element coexists

graphic p. 1120

graphic Usually history is diagnostic but occasionally, seizures of temporal lobe origin may have similar symptomatology.

Affects patients with DM—particularly those taking insulin or oral hypoglycaemic agents. Produces autonomic changes, e.g. pallor, sweating and tachycardia, and behavioural changes (confusion, altered personality). If action is not taken to ↑ blood sugar, coma ± fitting ensues—graphic p. 1100.

(e.g hallucinations—graphic p. 988).

Common presenting complaint. The skill lies in deciding which headaches are benign, needing no intervention, and which require action.

Is there >1 type of headache? Take a separate history for each.

Time When did the headaches start? New or recently changed headache calls for especially careful assessment. How often do they happen? Do they have any pattern? (e.g. constant, episodic, daily) How long do they last? Why is the patient coming to the doctor now? A headache diary over >8wk may help if long-standing headaches

Character Nature/quality, site, and spread of the pain. Associated symptoms, e.g. nausea/vomiting, visual disturbance, photophobia, neurological symptoms

Cause Predisposing and/or trigger factors; aggravating and/or relieving factors; relationship to menstrual cycle; family history

Response Details of medication used (type, dose, frequency, timing). What does the patient do, e.g. can the patient continue work?

Health between attacks Do headaches go completely or is the patient unwell between attacks? Other past/current medical problems

Anxieties and concerns Of the patient/family

In acute, severe headache, examine for fever and purpuric skin rash. In all cases check BP, brief neurological examination including fundi, visual acuity, and gait, palpation of the temporal region/sinuses for tenderness, and examination of the neck. In young children, measure head circumference and plot on a centile chart.

graphic Red flags

Fever and worsening headache ± purpuric rash/meningism

Thunderclap headache (reaching peak intensity in <5min)

Progressive headache, worsening over weeks

Headache associated with postural change, sneezing, coughing, or exercise

Recent head injury (<3mo)

Papilloedema

Change in personality/new cognitive or neurological deficit

New onset in a patient with a history of HIV or cancer.

Headache with atypical aura (>1h ± motor weakness)

Aura for first time and using CHC

Often not needed. ESR if temporal arteritis is suspected.

See Table 16.8. ↑ BP may cause acute or chronic headache. Direct treatment at the cause.

Table 16.8
Differential diagnosis of headache
Cause Features Management

Acute new headache

Meningitis

Fever, photophobia, stiff neck, rash

IV/IM penicillin V and immediate admission (graphic p. 1078)

Encephalitis

Fever, confusion, ↓ conscious level

Immediate admission (graphic p. 1078)

Subarachnoid haemorrhage

‘Thunder-clap’ or very sudden onset headache ± stiff neck

Immediate admission (graphic p. 560)

Head injury

Bruising/injury; ↓ conscious level, periods lucidity, amnesia

Consider admission (graphic p. 1112)

Self-limiting viral illness

Vary. Often associated with other symptoms, e.g. coryza, sore throat, low-grade fever

Paracetamol/NSAID—review if worsens or if not settling in 2–3d

Sinusitis

Tender over sinuses ± history of URTI

graphic p. 942

Dental caries

Facial pain ± tenderness

graphic p. 932

Tropical illness

History of travel, fever

graphic p. 648

Acute recurrent headache

Migraine

Aura, visual disturbance, nausea/vomiting, triggers

graphic p. 554

Cluster headache

Nightly pain in 1 eye for 2–3mo, then pain-free for >1y

graphic p. 556

Exertional or coital headache

Suggested by history of association

NSAID or propranolol before attacks

Trigeminal neuralgia

Intense stabbing pain lasting seconds in trigeminal nerve distribution

graphic p. 557

Glaucoma

Red eye, haloes, ↓ visual acuity, pupil abnormality

graphic p. 976

Subacute headache

Giant cell arteritis

>50y, scalp tenderness, ↑ ESR, rarely ↓ visual acuity

graphic p. 524

Chronic headache

Tension type headache

Band around the head, stress, low mood

graphic p. 556

Cervicogenic headache

Unilateral or bilateral; band from neck to forehead; scalp tenderness

graphic p. 474

Medication overuse

Rebound headache on stopping analgesics

graphic p. 557

↑ intracranial pressure

Worse on waking/sneezing, ↓ pulse, ↑ BP, neurological signs

graphic p. 558

Paget’s disease

>40y, bowed tibia, ↑ alk phos

graphic p. 504

Cause Features Management

Acute new headache

Meningitis

Fever, photophobia, stiff neck, rash

IV/IM penicillin V and immediate admission (graphic p. 1078)

Encephalitis

Fever, confusion, ↓ conscious level

Immediate admission (graphic p. 1078)

Subarachnoid haemorrhage

‘Thunder-clap’ or very sudden onset headache ± stiff neck

Immediate admission (graphic p. 560)

Head injury

Bruising/injury; ↓ conscious level, periods lucidity, amnesia

Consider admission (graphic p. 1112)

Self-limiting viral illness

Vary. Often associated with other symptoms, e.g. coryza, sore throat, low-grade fever

Paracetamol/NSAID—review if worsens or if not settling in 2–3d

Sinusitis

Tender over sinuses ± history of URTI

graphic p. 942

Dental caries

Facial pain ± tenderness

graphic p. 932

Tropical illness

History of travel, fever

graphic p. 648

Acute recurrent headache

Migraine

Aura, visual disturbance, nausea/vomiting, triggers

graphic p. 554

Cluster headache

Nightly pain in 1 eye for 2–3mo, then pain-free for >1y

graphic p. 556

Exertional or coital headache

Suggested by history of association

NSAID or propranolol before attacks

Trigeminal neuralgia

Intense stabbing pain lasting seconds in trigeminal nerve distribution

graphic p. 557

Glaucoma

Red eye, haloes, ↓ visual acuity, pupil abnormality

graphic p. 976

Subacute headache

Giant cell arteritis

>50y, scalp tenderness, ↑ ESR, rarely ↓ visual acuity

graphic p. 524

Chronic headache

Tension type headache

Band around the head, stress, low mood

graphic p. 556

Cervicogenic headache

Unilateral or bilateral; band from neck to forehead; scalp tenderness

graphic p. 474

Medication overuse

Rebound headache on stopping analgesics

graphic p. 557

↑ intracranial pressure

Worse on waking/sneezing, ↓ pulse, ↑ BP, neurological signs

graphic p. 558

Paget’s disease

>40y, bowed tibia, ↑ alk phos

graphic p. 504

Headache, stiff neck, and photophobia. Associated with meningitis. May also be seen with encephalitis and SAH.

NICE Headaches in young people and adults (2012) graphic  www.nice.org.uk

Migraine affects 15% of the UK population. ♂:♀ ≈1:3. One in three experiences significant disability. Caused by disturbance of cerebral blood flow under the influence of 5HT.

Occurs with or without headache. Symptoms arise over ≥5min and last 5–60min before resolving completely. Diagnose if:

Visual symptoms, e.g. flickering lights, spots, lines; partial loss of vision

Sensory symptoms, e.g. numbness; paraesthesia and/or

Speech disturbance

Consider referral for further investigation if: motor weakness; double vision; visual symptoms affecting only one eye; poor balance or ↓ level of consciousness.

Moderate to severe unilateral or bilateral throbbing/pulsating headache that lasts 4–72h (1–72h in children) and prevents usual activities. May occur with or without aura and be associated with nausea/vomiting ± ↑ sensitivity to light/noise.

Episodic Occurs on <15d/mo

Chronic Occurs on ≥15d/mo over >3mo

graphic p. 552

Management of an acute attackN

Combination therapy with:

Triptan (e.g. sumatriptan 50–100mg po)—choice depends on cost. Not effective if taken before the headache develops. Stops 70–85% attacks. Start with lowest dose and ↑ as needed. If consistently ineffective try an alternative triptan. Consider nasal triptan as first-line if aged 12–17y

NSAID (e.g. naproxen 500mg bd) or  paracetamol (1g qds) ± antiemetic (e.g. prochlorperazine 5mg, metoclopramide 10mg, or domperidone 10–20mg)—even if no nausea/vomiting

If oral preparations are ineffective/not tolerated, offer metoclopramide 10mg pr or buccal prochlorperazine 3–6mg and consider adding a non-oral NSAID (e.g. diclofenac 100mg pr) or triptan (e.g. sumatriptan 20mg nasal spray or 6mg sc).

graphic Do not offer ergots or opioids for the acute treatment of migraine.

Repeat symptomatic treatments within their dose limitations—pre-emptively if recurrence is usual/expected. If using triptans, a second dose may be effective, but repeated dosing can cause rebound headache. Naratriptan and eletriptan are associated with relatively low recurrence rates.

Aims to control symptoms and minimize impact on the patient’s life. Cure is not a realistic aim.

Half have a trigger for their migraine. Consider:

Psychological factors Stress/relief of stress; anxiety/depression; extreme emotions, e.g. anger or grief

Environmental factors Loud noise, bright/flickering lights, strong perfume, stuffy atmosphere, VDUs, strong winds, extreme heat/cold

Food factors Lack of food/infrequent meals; foods containing monosodium glutamate, caffeine, and tyramine; specific foods, e.g. chocolate, citrus fruits, cheese; alcohol, especially red wine.

Sleep Overtiredness (physical/mental); changes in sleep patterns (e.g. late nights, weekend lie-in, shift work, holidays); long-distance travel

Health factors Hormonal changes (e.g. monthly periods, CHC, HRT, the menopause); ↑ BP; toothache or pain in the eyes, sinuses, or neck; unaccustomed physical activity

Assessment scales, e.g Migraine Disability Assessment Score (MIDAS—see Box 16.1  graphic p. 585), can be useful in assessing impact of symptoms on daily life and monitoring response to treatment.

Box 16.1
Migraine Disability Assessment Score (MIDAS)

Used to assess the impact of migraine symptoms on lifestyle.

Instructions Please answer the following questions about ALL the headaches you have had over the last 3mo. If you did not do the activity in the last 3mo, write 0.

1. On how many days in the last 3mo did you miss work or school because of your headache?

□ days

2. How many days in the last 3mo was your productivity at work or school ↓ by ≥½ because of your headaches? (Do not include days you counted in question 1 where you missed work or school)

□ days

3. On how many days in the last 3mo did you not do household work* because of your headache?

□ days

4. How many days in the last 3mo was your productivity in household work↓ by ≥½ because of your headaches? (Do not include days you counted in question 3 where you did not do household work)

□ days

5. On how many days in the last 3mo did you miss family, social, or leisure activities because of your headaches?

□ days

MIDAS score

TOTAL

□ days

A. On how many days in the last 3mo did you have a headache? (lf a headache lasted more than 1 day, count each day)

□ days

B. On a scale of 0–10, on average, how painful were these headaches? (Where 0 = no pain at all, and 10 = pain as bad as can it be)

1. On how many days in the last 3mo did you miss work or school because of your headache?

□ days

2. How many days in the last 3mo was your productivity at work or school ↓ by ≥½ because of your headaches? (Do not include days you counted in question 1 where you missed work or school)

□ days

3. On how many days in the last 3mo did you not do household work* because of your headache?

□ days

4. How many days in the last 3mo was your productivity in household work↓ by ≥½ because of your headaches? (Do not include days you counted in question 3 where you did not do household work)

□ days

5. On how many days in the last 3mo did you miss family, social, or leisure activities because of your headaches?

□ days

MIDAS score

TOTAL

□ days

A. On how many days in the last 3mo did you have a headache? (lf a headache lasted more than 1 day, count each day)

□ days

B. On a scale of 0–10, on average, how painful were these headaches? (Where 0 = no pain at all, and 10 = pain as bad as can it be)

Questions A and B measure the frequency of the migraine and the severity of pain. They are not used to reach the MIDAS score but provide extra information helpful for making treatment decisions.

Interpreting the MIDAS score

I

Score: 0–5

Minimal/infrequent disability

Tend to have little or no treatment needs. Can often manage with OTC medication. If infrequent severe attacks may require triptan

II

Score: 6–10

Mild/infrequent disability

May require medication for acute attacks, e.g. NSAID ± antiemetic or triptan

III

Score: 11–20

Moderate disability

Will need medication for acute attacks. Consider prophylaxis. Consider other causes for headaches, e.g. tension type headache

IV

Score: ≥21

Severe disability

Interpreting the MIDAS score

I

Score: 0–5

Minimal/infrequent disability

Tend to have little or no treatment needs. Can often manage with OTC medication. If infrequent severe attacks may require triptan

II

Score: 6–10

Mild/infrequent disability

May require medication for acute attacks, e.g. NSAID ± antiemetic or triptan

III

Score: 11–20

Moderate disability

Will need medication for acute attacks. Consider prophylaxis. Consider other causes for headaches, e.g. tension type headache

IV

Score: ≥21

Severe disability

* Unpaid work, such as housework, shopping, and caring for children and others.

Reassure. Instruct about management of acute attacks. A diary can be used to identify trigger factors, assess headache frequency, severity, medication usage/overusage, and response to treatment. Avoid trigger factors where possible. Give advice on relaxation techniques and stress management. Do not offer CHC to women with migraine, especially if aura (graphic p. 753).

Consider if ≥4 attacks/mo or severe attacks. ↓ attacks by ~50%. Try a drug for 2mo before deeming it ineffective. If effective, continue for 6mo then review to consider ↓ dose slowly before stopping.

1st-line Propranolol S/R 80–160mg od/bd or topiramate 25–50mg od/bd—start at low dose and ↑ dose every 2–4wk; graphic Topiramate is teratogenic and may interact with hormonal contraception

2nd-line Gabapentin (up to 1200mg/d in divided doses) or acupuncture (up to 10 sessions over 5–8wk)

3rd-line Botulinum type A toxin may be helpful for patients who have chronic migraine, do not have medication-overuse headache and have not responded to ≥3 different prophylactic medicationsN

Riboflavin 400mg od may ↓ frequency/intensity of headachesN; feverfew 200mg daily may↓ symptoms after 6wk useC.

Suspect if migraine occurs from 2d before to 3d after start of period on at least 2 out of 3 consecutive months (use headache diary). If predictable menstrual-related migraine that does not respond to standard acute treatment, consider frovatriptan (2.5mg bd) or zolmitriptan (2.5 mg bd/tds) on the days that migraine is expected.

graphic >1 type of headache may coexist—50% migraine sufferers develop tension type headache resulting in background pain between attacks. Consider each separately.

Headaches in young people and adults (2012)

Migraine (chronic)—botulinum toxin type A (2012)

Migraine Action Association graphic 0116 275 8317 graphic  www.migraine.org.uk

Migraine Trust graphic 020 7631 6970 graphic  www.migrainetrust.org

graphic p. 552

graphic p. 554

Prevalence 4%. Defined as any headache that occurs >15d/mo. Common causes: tension-type headache, cervicogenic headache (graphic p. 474), medication-overuse headache, migraine, errors of refraction (usually headache is mild, frontal, in the eyes themselves, and absent on waking). Treat the cause (may be >1).

Associated with stress and anxiety and/or functional or structural abnormalities of the head or neck. Prevalence ≈2%. ♀:♂ ≈2:1. Symptoms begin aged <10y in 15% patients. Prevalence ↓ with age. Family history of similar headaches is common (40%), but twin studies do not suggest a genetic basis. Distinguish between episodic and chronic tension-type headache:

Episodic Defined as headache lasting 30min–7d and occurring <180d/y (<15d/mo)

Chronic Headaches on ≥15d/mo (≥180d/y) for ≥3mo

In both cases pain:

Is bilateral, pressing, and/or tightening in quality

Of mild/moderate intensity

Is not associated with vomiting

Does not prohibit activities

Is not aggravated by physical activity

Reassure no serious underlying pathology. Try measures to alleviate stress—relaxation; massage; yoga; exercise. Treat musculoskeletal symptoms with physiotherapy.

Analgesics are of limited value and might make matters worse (see Medication-overuse headache).

Acute management Simple analgesia, e.g. paracetamol, ibuprofen. Avoid codeine-containing preparations and other opioids

Prophylaxis Acupuncture—up to 10 sessions over 5–8wk

Extremely painful headaches focussed around 1 eye with associated autonomic symptoms on that side (drooping eyelid, constricted pupil, red watery eye, runny or blocked nose, forehead sweating). Rare <20y of age. ♂:♀ ≈6:1. More common in smokers. Pain lasts 15–180min and occurs from 1x every 2d to 8x/day. Recurrences affect the same side. Onset is often predictable (1–2h after falling asleep; after alcohol). 2 patterns:

Episodic Remissions of >1mo

Chronic Remissions of <1mo in a 12mo period

Refer for specialist advice/neuroimaging for first bout of cluster headache. Drug treatments:

Acute attack 100% oxygen (>12L/min) for 10–20min; 5HT1 agonists, e.g. sumatriptan (6mg sc or 20mg nasal)—stops 75% in <15min

Prophylaxis Consider verapamil 80mg tds/qds if attacks are frequent (needs ECG monitoring—seek specialist advice if unfamiliar with use). More effective if initiated early at the start of a new cluster. Refer for specialist advice if no response to verapamil.

Persistent headache in patients with other causes of pain who are overusing analgesics. Affects 1 in 50 adults; ♀:♂ ≈5:1. Consider if headache develops/worsens when taking analgesic medication for ≥3mo. Implicated drugs include:

Triptans, opioids, ergots, or combination analgesics on ≥10d/mo

Paracetamol, aspirin, or NSAID on ≥15d/mo

Explain the condition to the patient. Advise stopping overused medication abruptly for at least 1mo. Provide follow-up and support over 4–8wk; warn that symptoms may worsen initially (day 3–7) before improving. Review treatment of any underlying problem (e.g. migraine or chronic musculoskeletal pain). Consider specialist referral if taking strong opioids or recurrent, failed attempts to stop medication overuse.

Treat the cause. Common causes include: trigeminal neuralgia; temporomandibular joint disorders; dental disorders; sinusitis; migrainous neuralgia; shingles and post-herpetic neuralgia. No cause is found in many patients—it is then termed atypical facial pain. Atypical facial pain may respond to simple analgesia with paracetamol or NSAID. If this fails, try nerve painkillers, e.g. amitriptyline 10–75mg nocte. If troublesome symptoms, refer to ENT, maxillofacial surgery, or neurology.

Paroxysms of intense stabbing, burning, or ‘electric shock’ type pain, lasting seconds to minutes in the trigeminal (V) nerve distribution; 96% unilateral. Mandibular/maxillary > ophthalmic division. Between attacks there are no symptoms. Frequency of attacks ranges from hundreds/d to remissions lasting years. Pain may be provoked by movement of the face (talking, eating, laughing) or touching the skin (shaving, washing). Can occur at any age but more common >50y. ♀ > ♂. Unknown cause but associated with MS.

Spontaneous remission may occur.

Carbamazepine Start at low dose, e.g. 100mg od/bd, and ↑ dose over weeks until symptoms are controlled. Usual dose ≈200–400mg tds. Oxcarbazine is an alternative

Pregabalin Start with 75mg bd. Increase as needed to a maximum of 300mg bd. If ineffective, consider combining with amitriptyline

Amitriptyline Start at a dose of 25mg at 5–7 p.m.—10mg if elderly. ↑ dose by 10–25mg every 5–7d to a maximum of 75mg in a single dose as needed. Consider combining with pregabalin if ineffective alone

<50y; neurological deficit between attacks; treatment with first-line agents fails—specialist options include lamotrigine, duloxetine, baclofen, phenytoin, or surgical intervention.

Headaches in young people and adults (2012)

Organization for the Understaning of Cluster Headaches (OUCH UK) graphic 01646 651 979 graphic  www.ouchuk.org

Trigeminal Neuralgia Association UK graphic 01883 370214 graphic  www.tna.org.uk

Raised intracranial pressure (↑ ICP) usually presents with increasing headache associated with drowsiness, listlessness, vomiting, focal neurology, and/or seizures. Causes include: 1° or 2° tumours, head injury, intracranial haemorrhage, hydrocephalus, meningitis, encephalitis, brain abscess, and cerebral oedema (2° to tumour, trauma, infection, ischaemia).

Clinical features of ↑ ICP

graphic If suspected, admit as an emergency.

Drowsiness

↓ conscious level

Irritability

VI nerve palsy

Papilloedema

Dropping pulse

Rising BP

Focal neurological signs—due to underlying pathology

Pupil changes—constriction, then dilatation

Symptoms/signs of a space-occupying lesion, but none is found. Usually occurs in young, obese women. Cause unknown. Treated with repeat lumbar puncture, ventriculo-peritoneal shunt, diuretics, or dexamethasone. Usually resolves—but 10% recur later.

May be single or multiple. Organisms reach the brain via the blood stream, direct implantation, or local extension from adjacent sites (e.g. sinusitis). Presents with ↑ ICP, focal neurological signs, systemic effects of infection, and/or local effects due to the cause. Usually, features develop over 2–3 wk—occasionally, more slowly; in the immunosuppressed, onset is rapid. If suspected, admit as an emergency. Treatment is with IV antibiotics ± surgical drainage. Mortality is 20–30%. 50% of survivors have long-term neurological deficit; 30% epilepsy.

1˚ tumours 70%. Classified by whether they are benign/malignant and cell type. Glioma is an umbrella term meaning tumour of nervous system origin. Common subtypes: astrocytoma, oligodendroglioma, glioblastoma multiforme, and ependymoma. Tumours of the meninges (meningiomas) and cerebral blood vessels (cerebellar haemangioblastomas) can also occur.

2˚ brain tumours 30%—usually from carcinoma of breast, lung, or melanoma—in 50%, tumours are multiple

graphic <1% of patients with headache have a brain tumour.

ICP 23–50% have papilloedema at presentation; headache 25–35%

Seizures 25–30%. Suspect in all adults who have a first seizure—especially if focal or with localizing aura. Refer for urgent assessmentN

Evolving focal neurology Depends on the site. >50% have focal neurology at presentation. Frontal lobe lesions tend to present late

False localizing signs Caused by ↑ ICP. VI nerve palsy (causing double vision) is most common due to its long intracranial course

Subtle personality change 16–20% at presentation—irritability, lack of application, lack of initiative, socially inappropriate behaviour

Local effects Skull base masses, proptosis, epistaxis

Stroke, MS, head injury, vasculitis, encephalitis, Todd’s palsy (graphic p. 574), metabolic/electrolyte disturbance, other causes of space-occupying lesion—aneurysm, abscess, chronic subdural haematoma, granuloma, cyst.

Gliomas all have <50% 5y survival. Depending on site, meningiomas and haemangioblastomas have better prognosis.

graphic Referral guidelines for suspected brain tumourN
Refer urgently (to be seen in <2wk)

Patients in whom a brain tumour is suspected with:

Symptoms related to the CNS, including:

Progressive neurological deficit

New-onset seizures

Unilateral sensorineural deafness

Headaches

Mental changes

Cranial nerve palsy

Headaches of recent onset accompanied by features suggestive of raised intracranial pressure, e.g.:

Vomiting

Drowsiness

Posture-related headache

Pulse-synchronous tinnitus

or accompanied by other focal or non-focal neurological symptoms, e.g. blackout, change in personality, or memory

A new, qualitatively different, unexplained headache that becomes progressively severe

Suspected recent-onset seizures

Consider urgent referral

In patients with rapid progression of:

Subacute focal neurological deficit

Unexplained cognitive impairment, behavioural disturbance or slowness, or a combination of these

Personality changes confirmed by a witness and for which there is no reasonable explanation even in the absence of the other symptoms and signs of a brain tumour

Consider non-urgent referral

Or discussion with specialist for unexplained headaches of recent onset:

Present for ≥1 mo

Not accompanied by features suggestive of ↑ intracranial pressure

Dilatation of the cerebral ventricles and accumulation of CSF. May be:

Communicating Due to ↓ reabsorption of CSF. Causes: post-meningitis; SAH (80% develop some degree of hydrocephalus); trauma; neoplastic infiltration in the subarachnoid space

Non-communicating CSF flow is blocked due to an obstruction within the ventricles. Due to congenital malformations, tumour, brain abscesss, SAH, meningeal scarring due to meningitis, or cranial trauma

In infants presents with macrocephaly (graphic p. 893); convulsions; developmental delay; and/or spasticity. In adults presents with ↑ ICP. Refer for urgent neurological assessment. graphic All patients with a CSF shunt should have pneumococcal vaccination.

NICE Referral guidelines for suspected cancer (2005) graphic  www.nice.org.uk

Brain & Spine Foundation graphic 0808 808 1000 graphic  www.brainandspine.org.uk

graphic p. 562

Spontaneous bleeding into the subarachnoid space. Incidence 15/100,000. ♀ > ♂. Peak age 35–65y. Frequently fatal. Causes:

No cause (15%)

Rupture of congenital berry aneurysm (70%)

Bleeding disorder

Mycotic aneurysm 2° to endocarditis (rare)

Arteriovenous malformation (15%)

Smoking, alcohol, ↑ BP, less common pre-menopause. Berry aneurysms may run in families and are associated with polycystic kidneys, coarctation of the aorta, and Ehlers–Danlos syndrome.

Typically presents as a sudden devastating headache—‘thunderclap headache’—often occipital

Rarely (6%) preceded by a ‘sentinel headache’ representing a small leak ahead of a larger bleed

Vomiting and collapse with loss of consciousness ± fitting ± focal neurology follow

May be nothing to find initially. Neck stiffness takes 6h to develop. In later stages:

Papilloedema

Retinal and other intraocular haemorrhages

Focal neurology

↓ level of consciousness

If suspected admit immediately as a medical emergency. Only 1 in 4 admitted with suspected SAH turn out to have one. In most no cause for the headache is found.

Bleeding is from bridging veins between cortex and venous sinuses, resulting in accumulation of blood between dura and arachnoid. Causes: trauma (may be trivial); idiopathic.

Age, alcohol, falls, epilepsy, anticoagulant therapy.

Often insidious and history may go back several weeks:

Fluctuation of conscious level (35%)

Physical and intellectual slowing

Sleepiness

Headache

Personality change

Unsteadiness on feet

Slowly evolving stroke (e.g. hemiparesis)

Symptoms/signs of ↑ ICP

Stroke, cerebral tumour, dementia.

If suspected, admit as a medical emergency for further investigation. Evacuation of clot is possible even in very elderly patients and often results in full recovery.

Blood accumulated between the dura and bone of the skull. Usually occurs after head injury.

Deterioration of level of consciousness after head injury that initially produced no loss of consciousness or after initial post-injury drowsiness has resolved. This ‘lucid’ interval may last anything from a few hours to a few days. May be accompanied by worsening headache, vomiting, confusion ± focal neurological signs.

If suspected, admit as an emergency for further investigation. Early evacuation of clot carries excellent prognosis. Outlook is less good if coma pre-op.

Clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting >24h or leading to death, with no apparent causes other than of vascular origin. Common and devastating condition—most common cause of adult disability in the UK. Half of all strokes occur in people >70y.

Cerebral infarction (~70%). Atherothrombotic occlusion or embolism. Sources of embolism: left atrium (AF) or left ventricle (MI or heart failure). Ischaemia causes direct injury from lack of blood supply

Intracerebral or subarachnoid haemorrhage (~19%). Haemorrhage causes direct neuronal injury and pressure exerted by the blood results in adjacent ischaemia

Rare causes Sudden ↓ BP, vasculitis, venous-sinus thrombosis, carotid artery dissection

Age

↑ BP

DM

AF

Previous stroke or TIA

MI

Artificial heart valves

Hyperviscosity syndromes

Smoking

Alcohol

Obesity

Low physical activity

History Sudden onset of CNS symptoms or stepwise progression of symptoms over hours or days

Examination Conscious level—may be ↓ or normal; neurological signs (including dysphagia and incontinence); BP; heart rate and rhythm; heart murmurs; carotid bruits; systemic signs of infection or neoplasm

Decompensation after recovery from previous stroke (e.g. due to infection, metabolic disorder); SOL—1° or 2° cerebral neoplasm; cerebral abscess; trauma—subdural haematoma, traumatic brain injury; epileptic seizure; migraine; MS.

Acute management

Admit all patients who have suffered an acute stroke to hospital. Treatment of stroke in a stroke unit ↓ mortality and morbidityC. Thrombolysis early after stroke results in better outcome, so do not delay referral until the patient is seen. If stroke is suspected admit directly to hospital by emergency ambulance.

graphic Do not give aspirin prior to admission.

History is as for stroke but recovery takes place within 24h of initial symptoms. Patients with a history of TIA have a 20% risk of stroke in the following month with highest risk in the first 72h. Risk can be predicted using the ABCD2 scoring system (see Table 16.9).

Table 16.9
ABCD2 scoring system predicting future risk of stroke
ABCD2 Feature Score

Age

<60y

0

≥60y

1

BP

Systolic ≥140 and/or diastolic ≥90

1

Clinical features

Unilateral weakness

2

Speech disturbance without weakness

1

Other

0

Duration

≥1h

2

10–59min

1

<10min

0

Diabetes

Patient is diabetic

1

Patient is not diabetic

0

ABCD2 Feature Score

Age

<60y

0

≥60y

1

BP

Systolic ≥140 and/or diastolic ≥90

1

Clinical features

Unilateral weakness

2

Speech disturbance without weakness

1

Other

0

Duration

≥1h

2

10–59min

1

<10min

0

Diabetes

Patient is diabetic

1

Patient is not diabetic

0

Scoring:  High risk: 6–7 points—8.1% 2-day risk of stroke (21% of patients)

Medium risk: 4–5 points—4.1% 2-day risk of stroke (45% of patients)

Low risk: 0–3 points—1% 2-day risk of stroke (34% of patients)

Admit if >1 TIA in <1wk. Consider admission/specialist assessment in <24h if the patient falls into a high/medium-risk group

If not admitting, once all symptoms have stopped, start aspirin 75mg od. Check blood for FBC, ESR, U&E, Cr, eGFR, lipids, and glucose. Consider clotting screen ± thrombophilia screening if FH of thrombosis. Check ECG and CXR

Start treatment for risk factors, e.g. advise to stop smoking, start antihypertensives if ↑ BP, start statin and dipyridamole S/R 200mg bd

Refer for urgent assessment (to be seen in <1wk) and further investigation to a specialist service, e.g. TIA clinic. Specialist investigations include: CT or MRI scan to confirm diagnosis, carotid Dopplers if carotid artery territory symptoms; echocardiogram if recent MI, CCF/LVF, or murmur

Form of TIA due to emboli passing through the retina. This causes brief loss of vision for a matter of minutes ‘like a curtain’. Management is as for TIA.

graphic p. 560

graphic p. 564

graphic p. 204 and p. 582

Royal College of Physicians National clinical guideline for stroke (2008) graphic  www.rcplondon.ac.uk

NICE Stroke: Diagnosis and initial management of acute stroke and TIA (2008) graphic  www.nice.org.uk

Stroke Association graphic 0303 3033 100 graphic  www.stroke.org.uk

Different Strokes graphic 0845 130 7172 graphic  www.differentstrokes.co.uk

Speakability graphic 0808 808 9572 graphic  www.speakability.org.uk

Stroke is a family illness. 40% carers suffer psychological distress starting <6wk after discharge. Involve carers/families. Provide information/support. Address psychosocial issues and physical disability.

Monitor and reassess frequently. Continue follow-up even when specialist services have finished. Monitor 2° prevention measures. Refer for more specialist rehabilitation if there is any deterioration in function

Aids/appliances can help. Patients/carers may be entitled to benefits

After stroke most patients are prescribed ≥1 drugs to ↓ risk of further stroke, but some have memory loss or problems opening containers. Provide verbal and written information about medicines and help with packaging, e.g. non-childproof tops

Patients with AF Use the CHA2DS 2-VASc score (Table 16.10) to predict stroke risk and need for anticoagulation if non-valvular AF, atrial flutter, or high risk of recurrence after cardioversion.

Table 16.10
CHA2DS2-VASc score
ConditionPointsScore

C

Congestive heart failure

1

0—Low risk—no antithrombotic therapy

1—Moderate risk—consider oral anticoagulation for men only

≥2—High risk—oral anticoagulation unless contraindicated

Target INR for warfarin: 2–3

Do not withhold anticoagulation just because risk of falling

H

Hypertension

1

A

Age >75y

2

A

Age 65–74y

1

D

DM

1

S

Female*

1

S

Prior stroke/TIA

2

VASc

Vascular disease e.g. MI, peripheral arterial disease, aortic plaque

2

ConditionPointsScore

C

Congestive heart failure

1

0—Low risk—no antithrombotic therapy

1—Moderate risk—consider oral anticoagulation for men only

≥2—High risk—oral anticoagulation unless contraindicated

Target INR for warfarin: 2–3

Do not withhold anticoagulation just because risk of falling

H

Hypertension

1

A

Age >75y

2

A

Age 65–74y

1

D

DM

1

S

Female*

1

S

Prior stroke/TIA

2

VASc

Vascular disease e.g. MI, peripheral arterial disease, aortic plaque

2

*

For women <65y with no other risk factors, CHA2DS2-VASc score = 0

graphic In all cases weigh benefit of treatment against potential harms. The HAS-BLED score may help with decision-making:

Hypertension (uncontrolled, systolic >160mmHg)—1 point

Abnormal liver function (cirrhosis, bilirubin >2x normal, ALT/AST/alk phos >3x normal)—1 point

Abnormal renal function (dialysis, Cr >200micromol)—1 point

Stroke history—1 point

Prior major bleed or predisposition to bleeding—1 point

Labile INR (<60% of the time in therapeutic range)—1 point

Elderly (age ≥65y)—1 point

Drugs predisposing to bleeding (e.g. antiplatelet agents, NSAIDs)—1 point

Harmful alcohol use—1 point

A score ≥3 indicates ↑ 1-year bleed risk on anticoagulation sufficient to justify caution before prescribing or more regular review

graphic p. 199

Patients with a history of stroke or TIA/amaurosis fugax have a 30–43% risk of recurrent stroke in <5y. Prevention focusses on ischaemic/embolic events which account for the majority of strokes. Preventative strategies include:

Stopping smoking—graphic p. 182

Regular exercise— graphic p. 180

Diet and achieving a satisfactory weight—graphic pp. 174179

Reducing salt intake—↓ salt of 3g/d leads to ↓ in stroke risk of 13%

Avoiding alcohol excess—predisposes to both ischaemic and haemorrhagic stroke through effects on BP—graphic pp. 184187

Start patients not taking warfarin, who have had a non-haemorrhagic stroke on CT/MRI on clopidogrel 75mg od long-termN (aspirin 75mg od + dipyridamole S/R 200mg bd if intolerant). For patients who have had a TIA start aspirin 75mg od + dipyridamole S/R 200mg bd (dipyridamole M/R 200mg bd alone if intolerant to aspirin).

For 1° and 2° stroke prevention, anticoagulate with warfarin or a novel anticoagulant if potential causes of cardiac thromboembolism, e.g. rheumatic mitral valve disease; prosthetic heart valves; dilated cardiomyopathy; or AF associated with valvular heart disease or prosthesis or with CHA2DS2-VASc score ≥ (consider ≥ if ♂)

graphic p. 248

Systolic and diastolic BP independently predict stroke. Risk escalates with increasing BP. A 5–6mmHg ↓ BP reduces risk by >30%

After stroke (but not after TIA) defer treating hypertension until >2wk after the event as ↑ BP may be physiological response—lowering BP decreases perfusion of the brain and may be harmful

Primary prevention A 22% ↓ in cholesterol using a statin results in a 30%↓ in stroke in individuals with no past history of stroke/TIA. Treat if patients meet criteria for coronary prevention (graphic p. 242)

Secondary prevention Treat all patients with a history of CVD with a statin regardless of baseline cholesterol. National Stroke Guidelines suggest treatment with a statin, e.g. simvastatin 40mg od, if total cholesterol is >3.5mmol/L unless contraindicated

Carotid endarterectomy ↓ mortality if carotid stenosis is symptomatic. Benefits ↓ as stenosis gets less—no evidence of benefit if <30% stenosis.

Patients without history of stroke/TIA 2% annual risk of stroke so surgery is controversial—in general risks outweigh benefits

Patients with a history of stroke /TIA Consider referral for carotid endarterectomy/carotid artery stenting if >70% carotid artery stenosis and no severe disability

Royal College of Physicians National clinical guidelines for stroke (2012) graphic  www.rcplondon.ac.uk

NICE Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (2010) graphic  www.nice.org.uk

Atrial fibrillation: the management of atrial fibrillation (2014)

Stroke Association graphic 0303 3033 100 graphic  www.stroke.org.uk

Syndrome of:

Tremor Coarse tremor, most marked at rest, ‘pill-rolling’

Rigidity Limbs resist passive extension throughout movement—lead-pipe rigidity—and juddering on passive extension of the forearm or pronation/supination—cogwheel rigidity

Difficulty in initiating movement

Slowness of movement  Mask-like or expressionless face, ↓ blink rate, ↓ fidgeting, ↓ peristalsis

Abnormal gait Small steps—shuffling gait—and flexed posture as if hurrying to keep up with feet—festinant gait

Micrographia Small handwriting

Parkinson’s disease (PD)

Other neurodegenerative diseases, e.g. Alzheimer’s disease, multisystem atrophy

Following encephalitis

Drugs, e.g. haloperidol, chlorpromazine, metoclopramide

Toxins, e.g. CO poisoning

Trauma

Normal pressure hydrocephalus

If possible, stop the implicated drug. If on an antipsychotic for schizophrenia do not stop treatment, but add an antimuscarinic (e.g. procyclidine 2.5mg tds). Consider switching to an atypical antipsychotic drug—take specialist advice.

Parkinsonism accompanied by absent vertical gaze and dementia. Due to progressive supranuclear palsy. J.C. Steele, J.C. Richardson, and J. Olszewski—Canadian neurologists.

Incurable, progressive, degenerative disease affecting the dopaminergic neurones of the substantia nigra in the brainstem, resulting in deficiency of dopamine and relative excess of acetylcholine transmitters. Cause: unknown. Lifetime risk: 1 in 40. ♂ = ♀. Peak age at onset: ≈65y, but 5–10% patients are diagnosed when <40y old. Prevalence ↑ with age. J. Parkinson (1755–1824)—English physician.

Neuropsychiatric—apathy, anxiety/depression, visual hallucinations, psychosis, dementia, pain, olfactory disturbance

Sleep—excessive daytime sleepiness, restless legs

Autonomic—drooling, postural hypotension, hyperhidrosis, urinary dysfunction, dysphagia, weight↓, constipation, sexual dysfunction

Aims to:

↓ symptoms and ↑ quality of life

↓ rate of disease progression

Limit side effects of treatment

graphic p. 199

Refer all patients to a specialist with an interest in Parkinson’s disease for confirmation of diagnosis, advice on management, and to access a multidisciplinary specialist rehabilitation team.

Liaise closely with the specialist rehabilitation team.

General principles graphic p. 204

Specific issues graphic p. 582

(BNF 4.9) Rarely achieves complete control of symptoms; 5–10% respond poorly. Treatment for PD should be consultant-initiated and is not started until symptoms cause significant disruption of daily activities. Options:

(e.g. bromocriptine, pergolide). Often used alone as first-line treatment. ↑ dose gradually, according to response and tolerability. Withdraw gradually. Can also be used in association with L-dopa to ↓ off times and motor impairment.

graphic Bromocriptine, pergolide, cabergoline, and lisuride have been associated with pulmonary, retroperitoneal, and pericardial fibrosis.

Check CXR ± spirometry, ESR, and creatinine before starting

Monitor for dyspnoea, persistent cough, chest pain, cardiac failure, abdominal pain, or tenderness

Precursor of dopamine. ↑ dopamine levels within the substantia nigra. Start with low dose and ↑ in small steps—aim to keep final dose as low as possible and a compromise between ↑ mobility and dose-limiting side effects (involuntary movements, psychiatric effects). Optimum dose interval varies between individuals.

Only effective for PD. Not effective for patients with parkinsonism due to other causes. Improves bradykinesia and rigidity > tremor

Often given with a co-drug (carbidopa or benserazide) which prevents peripheral breakdown of levodopa to dopamine but does not cross the blood–brain barrier

With time, there is ↓ response and troublesome side effects appear:

On-off effect—fluctuation between periods of exaggerated involuntary movements and periods of immobility

End-of-dose effect—duration of benefit after each dose reduces

Abnormal involuntary movements

Monoamine oxidase B inhibition (e.g selegiline, rasagaline). Used in severe PD in conjunction with levodopa to ↓ end-of-dose effect. Early use may postpone onset of treatment with levodopa

Amantadine Improves bradykinesia, dyskinesias, tremor, and rigidity. Introduce and withdraw slowly

Inhibition of enzymatic breakdown of dopamine (e.g. entacapone, tolcapone). For patients suffering from end-of-dose effect

A small proportion of carefully selected patients benefit from ‘deep brain stimulation’ (DBS).

graphic p. 130

graphic p. 220

NICE Parkinson’s disease: diagnosis and management in primary and secondary care (2006) graphic  www.nice.org.uk

Parkinson’s Disease Society graphic 0808 800 0303 graphic  www.parkinsons.org.uk

Multiple sclerosis (MS) is a chronic disabling neurological disease due to an autoimmune process of unknown cause. Characterized by formation of patches of demyelination (‘plaques’) throughout the brain and spinal cord. There is no peripheral nerve involvement.

It is the most common neurological disorder of young adults, with a lifetime risk of 1:1,000. Peak age of onset is 20–40y. ♀:♂ ≈2:1. There is a marked geographical variation—prevalence ↑ with latitude.

Depends on the area of CNS affected. Take a careful history—although a patient usually presents with a single symptom, history may reveal other episodes that have gone unheralded. Isolated neurological deficits are never diagnostic. The hallmark of MS is a series of neurological deficits distributed in time and space not attributable to other causes. Predominant areas of demyelination are optic nerve, cervical cord, and periventricular areas.

Pain on eye movement (optic neuritis)

Visual disturbance— ↓, blurring, or double vision

↓ balance and coordination

Sensory disturbance (e.g. numbness, tingling)

Pain (e.g. trigeminal neuralgia)

Fatigue

Depression

Transverse myelitis (graphic p. 572)

Problems with speech (e.g. slurred or slow)

Bladder problems (e.g. frequency, urgency, incontinence)

Constipation

Sexual dysfunction (e.g. impotence)

Cognitive changes (e.g. loss of concentration, memory problems)

Dysphagia

graphic Symptoms may be worsened by heat or exercise.

Benign MS (10%). Retrospective diagnosis. The patient has a few mild attacks and then complete recovery. There is no deterioration over time and no permanent disability

Relapsing-remitting MS (RRMS) 85% patients. Episodes of sudden ↑ in neurological symptoms or development of new neurological symptoms with virtually complete recovery after 4–6wk. With time remissions become less complete and residual disability accumulates

Secondary progressive MS (SPMS) After ~15y, 65% of patients with relapsing-remitting disease begin a continuous downward progression which may also include acute relapses

Primary progressive MS (PPMS) 10% patients. Steady progression from the outset with increasing disability

If suspected, refer to neurology for confirmation of diagnosis and support from the specialist neurological rehabilitation team.

↓ frequency and/or severity of relapses by ~30% and slow course of the disease. Options are β-interferon (for RRMS and SPMS), and glatiramer (for RRMS only). Prescription must be consultant-led under the NHS risk-sharing scheme—Table 16.11.

Table 16.11
Indications for β-interferon and glatiramer
β-interferon Glatiramer

Age

≥18y

≥18y

Contraindications

No contraindications present

No contraindications present

Walking distance

RRMS Can walk ≥100m without assistance

SPMS Can walk ≥10m without assistance

RRMS Can walk ≥100m without assistance

Relapses

RRMS ≥2 clinically significant relapses in the last year

SPMS Minimal ↑ in disability due to gradual progression and ≥2 disabling relapses in the past 2y

RRMS ≥2 clinically significant relapses in the last year

Stop if

Intolerable side effects

Pregnant/planning pregnancy

≥2 disabling relapses in <1y

Inability to walk (± assistance) persisting ≥6mo

2° progression with observable ↑ in disability over 6mo

Intolerable side effects

Pregnant or planning pregnancy

≥2 disabling relapse in <1y

Inability to walk (± assistance) persisting ≥6mo

2° progression

β-interferon Glatiramer

Age

≥18y

≥18y

Contraindications

No contraindications present

No contraindications present

Walking distance

RRMS Can walk ≥100m without assistance

SPMS Can walk ≥10m without assistance

RRMS Can walk ≥100m without assistance

Relapses

RRMS ≥2 clinically significant relapses in the last year

SPMS Minimal ↑ in disability due to gradual progression and ≥2 disabling relapses in the past 2y

RRMS ≥2 clinically significant relapses in the last year

Stop if

Intolerable side effects

Pregnant/planning pregnancy

≥2 disabling relapses in <1y

Inability to walk (± assistance) persisting ≥6mo

2° progression with observable ↑ in disability over 6mo

Intolerable side effects

Pregnant or planning pregnancy

≥2 disabling relapse in <1y

Inability to walk (± assistance) persisting ≥6mo

2° progression

Approved for treatment of highly active RRMS, despite treatment with β-interferon, or rapidly evolving severe RRMS. Prescription must be consultant-led.

Natalizumab Is associated with ↑ risk of opportunistic infection and progressive multifocal leucoencephalopathy (PML). If new/worsening neurological symptoms/signs refer to neurology immediately

Fingolimod Is associated with macular oedema in 0.4%; routine ophthalmological review is recommended 3–4mo after initiation

Treat episodes causing distressing symptoms or ↑ limitation with high-dose steroids e.g. prednisolone 500mg–2g od po for 3–5d. Alternatively refer for high-dose IV steroids. Refer to specialist neurological rehabilitation if residual deficit or if frequent relapses.

Liaise closely with the specialist neurological rehabilitation team.

Screening for depression graphic p. 199

General principles of rehabilitation graphic p. 204

Common neurological rehabilitation problems graphic p. 582

NICE/RCP Diagnosis and management of multiple sclerosis in primary and secondary care (2003) graphic  www.nice.org.uk

MS Society A guide to MS for GPs and primary care professionals (2009) graphic  www.mssociety.org.uk

MS Society graphic 0808 800 8000 graphic  www.mssociety.org.uk

Is a degenerative disorder of unknown cause affecting motor neurones in the spinal cord, brainstem, and motor cortex. Prevalence in the UK ~4.5/100,000 population ♂:♀ ≈3:2. Peak age of onset ≈60y. 10% have a FH. There is never any sensory loss.

There are 3 recognized patterns of MND:

Amyotrophic lateral sclerosis (ALS) (50%). Combined LMN wasting and UMN hyperreflexia

Progressive muscular atrophy (25%). Anterior horn cell lesions, affecting distal before proximal muscles. Better prognosis than ALS

Progressive bulbar palsy (25%). Loss of function of brainstem motor nuclei (LMN lesions), resulting in weakness of the tongue, muscles of chewing/swallowing, and facial muscles

Combination of progressive upper and/or lower motor neurone signs, affecting >1 limb or a limb and the bulbar muscles. Symptoms and signs:

Stumbling (spastic gait, foot drop)

Tiredness

Muscle wasting

Weak grip

Weakness of skeletal muscles

Cramp

Fasciculation of skeletal muscles

Fasciculation of the tongue

Difficulty with speech (particularly slurring, hoarseness, or nasal or quiet speech)

Difficulty with swallowing

Aspiration pneumonia

graphic MND never affects eye movements (cranial nerves III, IV, VI)

Refer to neurology for exclusion of other causes of symptoms and confirmation of diagnosis. MND is incurable and progressive. Death usually results from ventilatory failure 3–5y after diagnosis.

Riluzole (50mg bd) is the only drug treatment licensed in the UK

Evidence suggests it extends life or time to mechanical ventilation for patients with ALS. It may also slow functional declineN

It should be initiated by a specialist with experience of MNDN

Monitoring of liver function is essential—monthly for the first 3mo; then 3-monthly for 9mo; then annually thereafter

Involve relevant agencies early, e.g. DN, social services, carer groups, self-help groups

Apply for all relevant benefits (graphic p. 222)

Screen for depression (graphic p. 199)

Discuss the future and patients’ wishes for the time when they become incapacitated with patient and carer(s)

Regular review to help overcome any new problems encountered is helpful for patients and carers

Spasticity—baclofen, tizanidine, botulinum toxin

Drooling—propantheline 15–30mg tds po or amitriptyline 25–50mg tds

Dysphagia—blend food, discuss NG tubes/PEG (graphic p. 583)

Depression—common. Reassess support, consider drug treatment, and/or counselling

Joint pains—analgesia

Respiratory failure—discuss tracheostomy/ventilation; weigh pros and cons of prolongation of life versus prolongation of discomfort

Palliative care  graphic pp. 10281047

(human spongiform encephalopathy). Fatal, degenerative brain disease due to a rogue form of brain protein or ‘prion’. Types:

Sporadic or classical Most common form in the UK (~50 cases/y). Rare <40y. Median duration of symptoms 3–4 mo. Cause: unknown

Variant Affects younger people than classical CJD and duration is longer, lasting a median of 14mo. Cause: transmitted by ingestion of nervous tissue in beef infected with bovine spongiform encephalitis or ‘mad cow disease’. Compensation may be available to families

Iatrogenic Cases associated with treatments using human growth hormone and human dura mater grafts. Rarely associated with corneal grafts or contaminated instruments used in surgery

Familial prion disease ~20–30 families in the UK are affected with a version of CJD passed from generation to generation in an autosomal dominant pattern. Median duration of symptoms from onset is 2–5y

Long incubation (>25y in some cases). Clinical features vary according to the areas of brain most affected but are always rapidly progressive. Common features: personality change; psychiatric symptoms; cognitive impairment; neurological deficits (sensory and motor deficits, ataxia); myoclonic jerks, chorea, or dystonia; difficulty with communication, mobility, swallowing, and continence; coma and death.

Dementia, depression, MS, MND, SOL.

There is no simple diagnostic test and often families feel frustrated by early misdiagnosis. Refer to neurologist if suspected. Treatment is supportive. Palliative care  graphic pp. 10281047

graphic p. 204

graphic p. 582

Riluzole for motor neurone disease (2004)

Motor neurone disease—non-invasive ventilation (2010)

Motor Neurone Disease Association graphic 08457 626262 graphic  www.mndassociation.org

Brain and Spine Foundation graphic 0808 808 1000 graphic  www.brainandspine.org.uk

Spinal cord injury tends to affect young people, especially young men. It is devastating, and the GP and primary care team are a vital part of the ongoing support network. Causes: trauma (42% falls; 37% RTAs), herniated disc, transverse myelitis, tumour, abscess.

Caused by spinal cord injury above the first thoracic vertebra. Usually results in paralysis of all four limbs, weakened breathing, and an inability to cough and clear the chest.

Occurs when the level of injury is below the first thoracic nerve. Disability can vary from the impairment of leg movement to complete paralysis of the legs and abdomen up to the nipple line. Paraplegics have full use of their arms and hands.

Anterior cord syndrome Damage is towards the front of the spinal cord, leaving the patient with loss or ↓ ability to sense pain, temperature, and touch sensations below the level of injury. Pressure and joint sensation may be preserved

Central cord syndrome Damage is in the centre of the spinal cord. Typically results in loss of function in the arms, but preservation of some leg movement ± some control of bladder/bowel function

Posterior cord syndrome Damage is towards the back of the spinal cord. Typically leaves patients with good muscle power, pain, and temperature sensation, but difficulty coordinating limb movements

Brown-Séquard syndrome Damage is limited to one side of the spinal cord resulting in loss or ↓ movement on the injured side but preserved pain and temperature sensation, and normal movement on the uninjured side but loss or ↓ in pain and temperature sensation. C.E. Brown-Séquard (1817–94)—French neurologist/physiologist

The spinal cord ends at L1/L2 at which point a bundle of nerves travels downwards through the lumbar and sacral vertebrae. Injury to these nerves causes partial or complete loss of movement and sensation. There may be some recovery of function with time.

Inflammation of the spinal cord at a single level. Symptoms develop rapidly over days/weeks and include limb weakness, sensory disturbance, bowel and bladder disturbance, back pain, and radicular pain. Recovery generally begins within 3mo but is not always complete. Causes:

Idiopathic (thought to be auto-immune mechanism)

Infection

Vaccination

Autoimmune disease, e.g. SLE, Sjögren’s syndrome, sarcoidosis

MS

Malignancy

Vascular, e.g. thrombosis of spinal arteries, vasculitis 2° to heroin abuse, spinal A-V malformation

Depending on severity of symptoms, admit as an acute medical emergency or refer for urgent neurological opinion.

Tubular cavities (syrinxes) form close to the central canal of the spinal cord. As the syrinx expands it compresses nerves within the spinal cord. Most common in patients with previous spinal injury—although may be years before. Typically presents with wasting and weakness of hands and arms, and loss of temperature and pain sensation over trunk and arms (cape distribution). Refer to neurology.

graphic p. 204

graphic p. 582

Reflex sympathetic overactivity, causing flushing and ↑ BP which may be severe. Only occurs in patients with lesions above T5/6. Usually triggered by discomfort below the level of the lesion. Presentation is with pounding headache, sweating, flushing, or mottling above the level of the lesion.

Sit the patient up and remove any obvious cause, e.g. pain, bladder distension, constipation. Give GTN spray (1–2 puff sublingual) or nifedipine 5–10mg capsule broken sublingually. If not settling, admit to hospital.

Most people with complete spinal cord injuries do not sweat below the level of the injury and many quadriplegics cannot sweat above the injury (even though they may sweat due to autonomic dysreflexia). With loss of ability to sweat or vasoconstrict, careful control of environmental conditions is essential to avoid hypothermia or overheating. In hot weather advise cooling with wet towels.

Many ♂ patients suffer infertility due to:

Failure of ejaculation

Retrograde ejaculation

Thermal damage due to sitting in a wheelchair → poor-quality sperm

Chronic infection of prostate and seminal vesicles (common)

Refer for specialist advice.

Both bladder and bowel function are reflex actions that we learn to override as children. If the lesion is above the level of this reflex pathway (T12 for bowel and T6 for bladder function) then automatic emptying will still occur when the bladder or bowel is full—though there is no control. If the lesion is below this level there is no emptying reflex. Bladder/bowel care programmes reflect this. Useful leaflets are available from the Spinal Injuries Association.

graphic p. 583

graphic p. 583

graphic p. 613

graphic p. 199

Spinal Injuries Association graphic 0800 980 0501 graphic  www.spinal.co.uk

Brain and Spine Foundation graphic 0808 808 1000 graphic  www.brainandspine.org.uk

Transverse Myelitis Society graphic  www.myelitis.org.uk

British Syringomyelia & Chiari Society graphic  www.britishsyringomyelia-chiarisociety.org

Epilepsy is a group of disorders in which fits or seizures occur as a result of spontaneous abnormal electrical discharge in any part of the brain. They take many forms but usually take the same pattern on each occasion for a given individual. Prevalence 5–10/1,000. 5% of those >21y old having their first fit have cerebral pathology (10% aged 45–55y).

graphic p. 898

graphic p. 1070

60% of adults who have one fit will never have another (90% if EEG is normal).

graphic Refer all patients with a first suspected seizure for urgent (within 2wk) assessment by a neurologist with training and expertise in epilepsy to exclude underlying causes (e.g. tumour) and receive clear guidance on medication, work, and driving N.

Is important, as these have implications for management and prognosis.

Partial seizures The seizure is limited to one area of the brain only. Termed ‘simple’ if no impairment of consciousness (previously called focal or Jacksonian epilepsy) and ‘complex’ if consciousness is impaired (previously called psychomotor or temporal lobe epilepsy). Partial seizures may become generalized

Generalized seizures Whole brain is involved. Consciousness is usually but not always impaired. 6 major types: tonic-clonic (grand mal); absence (petit mal); myoclonic; tonic; clonic; and atonic

graphic Some people have seizures that cannot be classified in this way.

Focal CNS signs (e.g. hemiplegia) following an epileptic seizure. The patient seems to have had a stroke but recovers in <24h.

A cause is found in more than two-thirds of people with epilepsy. The most common causes are:

Cerebrovascular disease

Cerebral tumours

Genetic, congenital, or hereditary conditions

Drugs, alcohol, and other toxic causes

Head trauma (including surgery)

Post-infective causes (e.g. meningitis, encephalitis)

See Table 16.12.

Table 16.12
Summary of points to cover during assessment
History

Background

Previous head injury

Alcohol/drug abuse

Meningitis or encephalitis

Stroke

Febrile convulsions

Family history of epilepsy

Provoking factors

Sleep deprivation

Alcohol withdrawal

Flashing lights

Prodrome/aura

Prodrome—precedes fit. May be a change in mood or behaviour noticed by the patient or others

Aura—part of the seizure that precedes other manifestations; odd sensations, e.g. déjà vu (odd feeling of having experienced that time before), strange smells, rising abdominal sensation, flashing lights

Features of the attack

Eye witness report: if available—colour of the patient, movement, length of fit, circumstances, after-effects

Memories of the patient: memories of the event and/or first memories after the event, frequency of attacks, relationship to sleep, menses, etc.

Residual symptoms after the attack

Bitten tongue

Incontinence of urine/faeces (not specific for epilepsy)

Confusion

Headache

Aching limbs or temporary weakness of limbs (Todd’s palsy)

Examination

Neurological examination

Fever, photophobia, neck stiffness, or petechial rash?

Any residual deficit

Focal neurology

Signs of ↑ ICP (graphic p. 558)

General examination

BP, heart sounds, heart rhythm and rate

Signs of systemic illness

Investigations (first fit only)

ECG

Blood for U&E, Cr, eGFR, LFT, Ca2+, FBC, ESR/CRP

Differential diagnosis

 

Vasovagal syncope

Psychogenic non-epileptic attacks (pseudo-seizures)

Tics

Panic attack

Hypoglycaemia

Normal phenomenon (e.g. déja vu)

Cardiac arrhythmias

Other cardiac disorders (e.g. aortic stenosis, HOCM)

TIA

Migrainous aura

History

Background

Previous head injury

Alcohol/drug abuse

Meningitis or encephalitis

Stroke

Febrile convulsions

Family history of epilepsy

Provoking factors

Sleep deprivation

Alcohol withdrawal

Flashing lights

Prodrome/aura

Prodrome—precedes fit. May be a change in mood or behaviour noticed by the patient or others

Aura—part of the seizure that precedes other manifestations; odd sensations, e.g. déjà vu (odd feeling of having experienced that time before), strange smells, rising abdominal sensation, flashing lights

Features of the attack

Eye witness report: if available—colour of the patient, movement, length of fit, circumstances, after-effects

Memories of the patient: memories of the event and/or first memories after the event, frequency of attacks, relationship to sleep, menses, etc.

Residual symptoms after the attack

Bitten tongue

Incontinence of urine/faeces (not specific for epilepsy)

Confusion

Headache

Aching limbs or temporary weakness of limbs (Todd’s palsy)

Examination

Neurological examination

Fever, photophobia, neck stiffness, or petechial rash?

Any residual deficit

Focal neurology

Signs of ↑ ICP (graphic p. 558)

General examination

BP, heart sounds, heart rhythm and rate

Signs of systemic illness

Investigations (first fit only)

ECG

Blood for U&E, Cr, eGFR, LFT, Ca2+, FBC, ESR/CRP

Differential diagnosis

 

Vasovagal syncope

Psychogenic non-epileptic attacks (pseudo-seizures)

Tics

Panic attack

Hypoglycaemia

Normal phenomenon (e.g. déja vu)

Cardiac arrhythmias

Other cardiac disorders (e.g. aortic stenosis, HOCM)

TIA

Migrainous aura

graphic p. 199

graphic p. 576

graphic p. 829

Death rate is ↑ x2–3. Deaths are related to underlying condition, accidents, SUDEP, or status epilepticus.

Probably due to central respiratory arrest during a seizure. Minimize risk by optimizing seizure control and being aware of potential consequences of night seizures.

Epilepsy Action graphic 0808 800 5050 graphic  www.epilepsy.org.uk

Regular GP review, at least annually, is essential.

Epilepsy is a diagnosis causing alarm and fear. Find out how much the patient (and family) understands about epilepsy. Acknowledge distress at diagnosis and answer their questions. Provide information on:

What to expect—fits are controlled with drugs in 80%

What to do during an attack

Driving (graphic p. 130) and work—stop driving, and notify DVLA and motor insurance company. Inform employer. Do not work at heights or with/near dangerous machinery

Avoiding risks—avoid cycling in traffic; only swim if lifeguard present

Importance of concordance with medication

When drug withdrawal may be considered if fit-free

Leaflets are available from Epilepsy Action. Support groups can help.

BNF 4.8.1. NICE recommends drug treatment (see Table 16.13) after the second seizure, except in specific circumstances. Drug choice is a specialist decision. graphic Patients on anticonvulsants are entitled to free prescriptions throughout the UK.

Table 16.13
Commonly used drugs in epilepsy. Stress the importance of concordance. Start at a low dose, and ↑ dose until fits are controlled or side effects occur. Use monotherapy wherever possible—two drugs ↑ toxicity and side effects. Polytherapy offers no advantage over monotherapy for 90% patients. Prescribe by brand name—generic prescribing may lead to changing of brand. Changing brand carries 10% risk of worsening of seizure control.
Ethosuximide Sodium valproate Carbamazepine Lamotrigine Clonazepam

Type of epilepsy

Absence

Myoclonic

Tonic clonic

1

Partial ± 2° generalized

Adult starting dose

500mg od

300mg bd

100–200mg od or bd

25mg od for 2wk2

1mg nocte for 4d

Incremental dose

250mg/d at weekly intervals

200mg/d at 3-day intervals

100mg/d at weekly intervals

From starting dose to 50mg od for 2wk, then ↑ by 50mg/d at weekly intervals

↑ according to response over 2–4wk

Usual daily dose

1–1.5g od

500mg–1g bd

200–1200mg

100–200mg

4–8mg nocte

Common/important side effects

Blood dyscrasias3, sedation, nausea, vomiting, dizziness, ataxia

Pancreatitis, liver toxicity4, blood dyscrasias3, sedation, tremor, weight ↑, hair thinning, ankle swelling

Blood dyscrasias3, rash, liver toxicity4, nausea, sedation, diplopia, dizziness, fluid retention, ↓ Na+  5

Blood dyscrasias3, rash, fever, influenza-like symptoms, drowsiness, or worsening of seizure control

Drowsiness/fatigue, amnesia/confusion/restlessness, muscle hypotonia, co-ordination problems, dependence, and withdrawal

Ethosuximide Sodium valproate Carbamazepine Lamotrigine Clonazepam

Type of epilepsy

Absence

Myoclonic

Tonic clonic

1

Partial ± 2° generalized

Adult starting dose

500mg od

300mg bd

100–200mg od or bd

25mg od for 2wk2

1mg nocte for 4d

Incremental dose

250mg/d at weekly intervals

200mg/d at 3-day intervals

100mg/d at weekly intervals

From starting dose to 50mg od for 2wk, then ↑ by 50mg/d at weekly intervals

↑ according to response over 2–4wk

Usual daily dose

1–1.5g od

500mg–1g bd

200–1200mg

100–200mg

4–8mg nocte

Common/important side effects

Blood dyscrasias3, sedation, nausea, vomiting, dizziness, ataxia

Pancreatitis, liver toxicity4, blood dyscrasias3, sedation, tremor, weight ↑, hair thinning, ankle swelling

Blood dyscrasias3, rash, liver toxicity4, nausea, sedation, diplopia, dizziness, fluid retention, ↓ Na+  5

Blood dyscrasias3, rash, fever, influenza-like symptoms, drowsiness, or worsening of seizure control

Drowsiness/fatigue, amnesia/confusion/restlessness, muscle hypotonia, co-ordination problems, dependence, and withdrawal

1

Drug of choice for primary syndromes of generalized epilepsy.

2

Starting dose is different if used in association with other epileptics—see BNF.

3

Check FBC if bruising, mouth ulcers, or symptoms of infection (sore throat, fevers).

4

Warn about symptoms of liver disease. Check LFTs soon after starting and at review.

5

Monitor U&E at regular review.

Consider if fit-free for 2–3y. Decision to stop must be the patient’s. Balance problems/inconvenience of drug- taking against risks of fits. Refer to neurology for supervision of drug withdrawal. If adult with grand mal epilepsy, 59% stay fit-free for 2y.

generalized tonic-clonic seizures; myoclonic epilepsy or infantile spasms; taking >1 drug for epilepsy; ≥1 seizure after starting treatment; duration of treatment >10y; fit-free <5y.

graphic Advise patients not to drive during withdrawal of epileptic medication or for 6mo afterwards.

Used for intractable partial seizures, hemiepilepsy, and epilepsy with focal EEG and/or radiological features.

↓ frequency of seizures for those refractory to anti-epileptic medication but not suitable for resective surgery.

Effective in some patients with refractory epilepsy—take specialist advice.

Review the individual’s care plan. Record fits and precipitating causes; check drug concordance (frequency of repeat prescriptions) and side effects; if fit-free >2y—discuss the possibility of withdrawing medication, if appropriate. For women of reproductive age give contraception (graphic p. 756) and pre-conception advice (graphic p. 829).

For review by a neurologist or epilepsy nurse specialist if:

Control is poor or drugs are causing unacceptable side effects

Seizures have continued despite medication for >2y or on two drugs

Pointers to a previously unsuspected cause for the fits appear

Concurrent illness (physical or psychiatric) complicates management

For pre-conceptual advice or to discuss withdrawal of medication

Muscle weakness, fatigability. Pain at rest suggests inflammation—pain on exercise, ischaemia, or metabolic myopathy.

Look for associated systemic disease.

Myotonia—delayed muscular relaxation after contraction, e.g. difficulty letting go after gripping something

Local muscular tenderness or firm muscles—may be due to infiltration of muscle with connective tissue or fat

Fasciculation—spontaneous, irregular, and brief contractions of part of a muscle; suggests LMN disease, e.g. MND

Lumps—tumours are rare; lumps may be due to tendon rupture, haematoma, or herniation of muscle through fascia

Group of genetic disorders characterized by progressive degeneration and weakness of some muscle groups.

Autosomal dominant inheritance—abnormal DMPK gene on chromosome 19. Presents at any age. Symptoms vary from mild to severe and may include:

Muscle symptoms—weakness and myotonia, particularly involves face, eyelids, jaw, neck, forearms/hands, lower legs/feet. Can affect speech and result in a lack of facial expression

Respiratory symptoms—weakness of respiratory muscles → poor night-time sleep, daytime sleepiness, headaches, and difficulty waking; aspiration → recurrent chest infections

Eye symptoms—cataract (may be the only problem) and ptosis

Reproductive problems—infertility as a result of atrophy of the testes and problems in labour due to uterine muscle weakness

Learning difficulty and behavioural problems

Digestive symptoms—swallowing difficulty, abdominal pain, constipation/diarrhoea, gallstones

Cardiac arrhythmias—annual ECG is advisable

Endocrine abnormalities, e.g. DM

Anaesthetic problems—pre-warn anaesthetist/surgeon prior to surgery

Prognosis is variable depending on severity of symptoms. Refer to confirm diagnosis and for advice on management/genetic counselling.

graphicDuchenne’s muscular dystrophy

Sex-linked recessive inheritance means almost always confined to boys. 30% of cases are due to spontaneous mutation. Investigation shows markedly ↑ CK (>40x normal). Presents typically at ~4y with progressively clumsy walking. Few survive to >20y old. Refer for confirmation of diagnosis and ongoing specialist support. Genetic counselling is important. G.B.A. Duchenne (1807–75)—French neurologist.

Myotonic Dystrophy Support Group  graphic 0115 987 0080 graphic  www.myotonicdystrophysupportgroup.org

Muscular Dystrophy Campaign  graphic 0800 652 6352 graphic  www.muscular-dystrophy.org

Certain drugs can cause myopathy including:

Alcohol

Labetalol

Cholesterol-lowering drugs (including statins)

Steroids

Chloroquine

Zidovudine

Vincristine

Ciclosporin

Cocaine

Heroin

PCP

Stop the implicated drug immediately. If symptoms do not resolve, refer for confirmation of diagnosis and management advice.

Often a manifestation of systemic disease, e.g. thyroid disease (especially hyperthyroidism), carcinoma, Cushing’s disease. Investigate to find the cause. Treat the cause if found else refer for further investigation.

Insidious, symmetrical, proximal muscle weakness due to muscle inflammation. Dysphagia, dysphonia, and/or respiratory muscle weakness may follow. 25% have a purple rash on cheeks, eyelids, and other sun-exposed areas (dermatomyositis) ± nail fold erythema. CK levels are ↑. Associated with malignancy in 10% of patients >40y. Refer.

Spread: droplet or faecal-oral. Incubation: 7d. Presents with 2d flu-like prodrome then fever, tachycardia, headache, vomiting, stiff neck, and unilateral tremor (‘pre-paralytic stage’). 65% who experience the pre-paralytic stage go on to develop paralysis (myalgia, LMN signs ± respiratory failure). Management: supportive—admit to hospital. <10% of those developing paralysis die. Permanent disability may result.

1º immunization in babies and children <10y 3 doses of the 5-part vaccine (DTaP/IPV/Hib), protecting against polio, diphtheria, whooping cough, tetanus, and Haemophilus influenzae, each 1mo apart—usually at 2mo, 3mo, and 4mo. If schedule is disrupted resume where stopped

Booster doses in children 1 dose of 4-part vaccine (DTaP/IPV), protecting against polio, diphtheria, whooping cough, and tetanus >3y after the 1° course (usually pre-school), and another dose of 3-part vaccine (Td/IPV) against tetanus, diphtheria, and polio, 10y later (age 13–18y)

1º immunization in children >10y and adults Three doses of 3-part vaccine (Td/IPV), each 1mo apart. Give booster doses after 3y and 10y

Booster doses for travel Not required unless at special risk, e.g. travelling to endemic/epidemic area or healthcare workers. Boosters of Td/IPV are then given every 10y

20–30y after initial infection some patients develop new symptoms often triggered by a period of immobilization:

↑ muscle weakness and fatigue

Pain in muscles and joints

Respiratory difficulties (particularly in those who spent some time in an iron lung ventilator)—may present with symptoms relating to sleep

Once other causes are excluded, treatment is supportive.

graphic p. 570

graphic p. 548

Autosomal dominant trait. Criteria for diagnosis: ≥2 of:

≥6 café-au-lait patches (flat, coffee-coloured patches of skin seen in first year of life, increasing in number and size with age) >5mm (pre-pubertal) or >15mm (post-pubertal)

≥2 neurofibromas:

Dermal neurofibromas—small violaceous skin nodules which appear after puberty

Nodular neurofibromas—subcutaneous, firm nodules arising from nerve trunks (may cause paraesthesiae if compressed) or a plexiform neurofibroma which appears as a large subcutaneous swelling

Freckling in axilla, groin, neck base, and submammary area (women). Present by age 10y

≥2 Lisch nodules—nodules of the iris only visible with a slit lamp

Distinctive bony abnormality specific to NF1, e.g. sphenoid dysplasia

First-degree relative with NF1

Ongoing specialist management is essential.

Affect 1 in 3 patients:

Mild learning disability

Short stature

Macrocephaly

Nerve root compression

GI bleeding or obstruction

Cystic bone lesion

Scoliosis

Pseudoarthrosis

↑ BP (6%)—due to renal artery stenosis or phaeochromocytoma

Malignancy (5%)—optic glioma or sarcomatous change of neurofibroma

Epilepsy (slight ↑)

F.D. von Recklinghausen (1833–1910)—German pathologist.

Much rarer than type 1. Autosomal dominant inheritance.

One of:

Bilateral vestibular schwannoma (acoustic neuroma—sensorineural hearing loss, vertigo ± tinnitus)

First-degree relative with NF2 and either a unilateral vestibular schwannoma or ≥1 neurofibroma, meningioma, glioma, schwannoma, or juvenile cataract

Screen at-risk patients with annual hearing tests. Once diagnosis is made, specialist neurosurgical management is needed.

Schwannomas of other cranial nerves, dorsal nerve roots, or peripheral nerves; meningioma (45%); other gliomas (less common).

The patient (who is usually in bed) is seized by an irresistible desire to move his/her legs in a repetitive way accompanied by an unpleasant sensation deep in the legs. Sleep disturbance is common, as is +ve FH. Cause: unknown.

Exclude drug causes—common culprits: β-blockers, H2 antagonists, neuroleptics, lithium, TCAs, anticonvulsants

Exclude peripheral neuropathy or ischaemic rest pain

Iron deficiency (with or without anaemia) is associated in 1 in 3 sufferers so check FBC and serum ferritin

Also check: U&E, Cr, eGFR, fasting blood glucose, and TFTs

Try non-drug measures first—reassurance, information, walking/stretching, warmth, relaxation exercises, massage

Drugs—dopamine agonists are often effective, e.g. ropinirole, pramipexole

Refer if severe symptoms or diagnosis is in doubt

K.A. Ekbom (1907–77)—Swedish neurologist

RLS-UK  graphic 01634 260483 graphic  www.rls-uk.org

Thiamine deficiency causing nystagmus, ophthalmoplegia, and ataxia. Other eye signs, e.g. ptosis, abnormal pupillary reactions, and altered consciousness or confusion may also occur. Consider in any patient with symptoms and a history of alcoholism.

Refer for confirmation of diagnosis. Meanwhile start thiamine 200–300mg od po to prevent irreversible Korsakoff’s syndrome. In severe cases admit as a medical emergency. K. Wernicke (1848–1904)—German psychiatrist.

↓ ability to acquire new memories. May follow Wernicke’s encephalopathy and is due to thiamine deficiency. Confabulation to fill gaps in memory is a feature. Refer for specialist advice on management. S.S. Korsakoff (1853–1900)—Russian neuropsychiatrist.

graphic p. 911

Autosomal dominant trait. Testing can identify affected individuals before symptoms occur. Pre-conceptual and antenatal testing is available and should be offered to any couple with a family history on either the mother’s or the father’s side. Presents with movement abnormalities (e.g. hemichorea and rigidity) and dementia. Memory is relatively spared compared to cognition. Refer for expert advice. G. Huntington (1851–1916)—US physician.

The most common inherited ataxia (autosomal recessive). Prevalence—1:50,000. Presents in adolescence with progressive gait and limb ataxia, loss of proprioception, pyramidal weakness, and dysarthria. Extra-neurological involvement includes hypertrophic cardiomyopathy (most patients) and DM (10%). Treatment is supportive. Most patients become chairbound with in 15y and die in the 4th or 5th decade from cardiac or pulmonary complications. N. Friedreich (1825–82)—German neurologist.

Ataxia UK graphic 0845 644 0606 graphic  www.ataxia.org.uk

New symptoms or limitations

Consider:

Is it due to an unrelated disease (e.g. change in bowel habit in someone who has had a stroke might indicate bowel cancer)?

Is it due to an incidental infection (e.g. UTI, chest infection)?

Is it due to a relapse (e.g. acute relapse in MS, TIA or further stroke in a stroke patient)?

Is it due to a side effect of treatment (e.g. acute confusion, involuntary movements or the on-off effect in a patient with PD)?

Is it part of a gradual progression (e.g. in MS, MND, brain tumour)?

Treat any cause of deterioration identified. If no cause is found, consider re-referring for specialist review and/or referring to the multidisciplinary rehabilitation team involved with the patient.

graphic p. 204

Consider and treat factors that might be responsible:

Depression

Chronic pain

Disturbed sleep

Poor nutrition

Review support, diet, and medication; encourage graded aerobic exercise; consider a trial of amantadine 200mg/d to improve symptomsN.

Common. Diagnosis can be difficult. Standardized questionnaires, e.g. PHQ-9 (graphic p. 1001), are helpful for screening.

Give opportunities to talk about the impact of the illness on lifestyle. Jointly identify areas where positive changes could be made, e.g. referral to day care to widen social contact. Consider referral for counselling or to a self-help/support group. Consider antidepressant medication and/or referral to psychiatric services.

If the patient cries (or laughs) with minimal provocation, consider emotionalism—impairment in the control of crying. Reassure.

Problems are common. Useful information sheets are available at graphic  www.outsiders.org.uk

Speech therapy assessment is vital. Consider support via dysphasia groups and communication aids, e.g. simple pointing board (take advice from speech therapy and OT).

Refer to an optician in the first instance. If corrected vision is still poor refer for ophthalmology review.

Common. Treat with antibiotics unless in terminal stages of disease. Advise pneumococcal and influenza vaccination.

Common but clinically apparent in <5%. Ensure adequate hydration and encourage mobility. Consider use of aspirin 75–150mg od and compression stockings if immobile. Prophylactic anticoagulation does not improve outcome.

Aim to maintain physical independence:

Involve physiotherapy—often only 2–3 visits are needed

Involve OT—a task-oriented approach is used (e.g. learning how to dress). Can also supply/advise on aids and appliances, e.g. Velcro fasteners, wheelchairs, adapted cutlery, etc

Refer for social services OT assessment if aids, equipment, or adaptations are needed for the home

Refer for home care services as necessary

Give information about driving (graphic pp. 128131) and/or employment where appropriate

Treat with physiotherapy (usually involving exercise ± splinting) ± drugs. Anti-spasticity drugs include dantrolene (25mg od), baclofen (5mg tds or rarely through a pump), and tizanidine (2mg od). Botulinum toxin can be directed at specific muscles. Refer via the specialist rehabilitation team.

Most pain arises from ↓ mobility. Other causes include: pre-morbid disease (e.g. osteoarthritis); central pain due to neurological damage; and neuropathic pain.

Chronic pain, especially central pain, may respond to TCAs. Peripheral pain may respond to simple analgesia ± physiotherapy. Other options are TENS and local joint injection. A cannabinoid is now available as an oromucosal spray (Sativex®) for relief of pain/muscle spasm in MS on specialist prescription only. Refer patients with intractable pain to specialist pain clinics.

UTI If suspected, check urine dipstick ± send MSU for M,C&S and start antibiotics. If >3 proven UTIs in 1y refer to specialist incontinence service or urology for further assessment

Incontinence  graphic pp. 450453

Nocturia Desmopressin 100–400 micrograms po or 10–40 micrograms intranasally may be helpful

Urgency Modify environment, e.g. provide commode; try anticholinergic, e.g. tolterodine 2mg bd or oxybutinin 5mg tds. If not settling refer for specialist assessment

Dysphagia Common. Fluids are more difficult to swallow than semisolids. Formal assessment by trained staff is essential. Feeding through NG tube or percutaneous endoscopic gastrostomy (PEG) may be needed long- or short-term—in terminal disease (e.g. MND), weigh provision of nutrition against prolongation of poor-quality life

Constipation Difficulty with defecation or BO <2x/wk—↑ fluid intake and ↑ fibre in diet. If no improvement, use po laxative ± regular suppositories/enemas

Incontinence Exclude overflow due to constipation

Prevented by: positioning; mobilization; good skin care; management of incontinence; pressure-relieving aids (e.g. special mattresses/cushions). Involve community nursing services.

A number of neurological assessment scales are in common use. Agreeing to use a formal, validated assessment scale enables comparison of observations between different team members, and also allows comparison of observations over time. Commonly used scales include:

Assesses level of consciousness—graphic p. 1068

Assesses muscle power

0—no muscle movement

1—muscle flicker but no movement

2—moves but not against gravity

3—supports limb against gravity but not resistance

4—able to overcome mild resistance (mild weakness)

5—able to overcome strong resistance (normal power)

Assess the impact of a particular condition on the individual. These scales are usually condition specific, e.g. the Migraine Disability Assessment Scale (MIDAS)—see Box 16.1, or Seizure Severity Questionnaire for patients with epilepsy. These scales are useful to gauge severity of symptoms and also monitor response to any treatments provided.

A number of scales are available that measure what the individual can do in practice. These may be:

Non-disease specific e.g. Barthel Index, or

Disease specific e.g. Oxford Stroke Handicap Scale

It is not really important which scale is used as long as everyone in the team uses the same scale for any given patient. Most use a graded Likert scale (e.g. 0–5) and rate activities such as:

Mobility—walking, stairs, ability to transfer

Personal care—dressing, washing

Feeding—ability to prepare food, ability to feed self

Toileting—ability to use the toilet, continence (bowels and bladder)

Neurological conditions can have a profound impact on quality of life. Scales used to assess impact on quality of life may be completed by the patients themselves, or by the attending health professional. Examples include:

Non-disease specific scales e.g, Euroqol EQ-5D

Disease specific scales, e.g. Quality of Life in Essential Tremor (QUEST); Quality of Life in Epilepsy (QUOLIE)

e.g. The General Practitioner Assessment of Cognition (GPCOG), or 6 Cognitive Impairment Test (6CIT—graphic p. 1011).

e.g.

Anxiety—GAD-2 (graphic p. 993)

Depression—NICE Chronic disease depression screening questions (graphic p.199); PHQ-9 (graphic p. 1001)

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close